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This dissertation is focused on dietary choline and its derivative trimethylamine-N-
oxide (TMAO). Recent discoveries have implicated circulating TMAO as a candidate 
risk factor for cardiovascular disease (CVD) among patients, but whether TMAO and 
dietary choline play a causative role in the disease process remains controversial. This 
dissertation describes 1) the production of TMAO from its dietary precursors (TMAO, 
choline and L-carnitine) in healthy individuals, 2) its metabolic fate within the body, 
and 3) the relationship between dietary choline and high blood pressure, a major risk 
factor for CVD. 
In Chapter 1, a randomized crossover feeding study was conducted where 40 
healthy men consumed a test meal consisting of either fish (TMAO), eggs (choline), 
beef (choline and L-carnitine) or a fruit control. Postprandial blood collected for 6 
hours after consumption of the test meal revealed that fish consumption yielded the 
highest increase in plasma TMAO metabolites among the test meals. Furthermore, 
production of TMAO following consumption of eggs or beef varied among individuals 
and correlated with the gut microbiome. The overall findings show that TMAO can be 
temporarily elevated in healthy individuals following consumption of various foods, 
especially heart-healthy fish. High variation in plasma TMAO in response to the same 
   iv 
meals indicates metabolic differences among individuals that may be due to other 
factors such as composition of the gut microbiome. 
In Chapter 2, the metabolic fate of dietary TMAO was investigated. Participants 
enrolled in the feeding study consumed 50 mg deuterium-labeled methyl d9-TMAO 
(d9-TMAO) in the fruit control arm. We found that d9-TMAO entered circulation 
within 15 min and that 96% of the tracer was excreted in urine within 24 hours. These 
results demonstrate rapid absorption of intact TMAO along with its efficient 
elimination from the human body. 
In Chapter 3 the hypothesis that increased choline intake may increase CVD risk 
through elevated blood pressure was investigated. Using cross-sectional 2007-10 
National Health and Nutrition Examination Survey, we examined the relationship of 
choline intake with blood pressure and prevalence odds of hypertension in a general 
U.S. population. We found a borderline inverse association between choline intake and 
odds of hypertension in women but not in men. Furthermore, supplemental choline use 
by both sexes showed a significant inverse association with hypertension. We 
concluded that choline intake is not associated with blood pressure, a risk factor of 
CVD, in this population.  
Taken together, evidence in this dissertation does not support the hypothesis that 
dietary choline increases disease risks by elevating baseline circulating TMAO in 
healthy adults. More epidemiologic and experimental evidence are still needed to 
further confirm or dispute this hypothesis. 
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INTRODUCTION 
 
OVERVIEW 
Choline is a quaternary ammonium cation (C5H14NO+) that is a part of several 
metabolites including acetylcholine, glycerophosphocholine, phosphocholine 
phosphatidylcholine (PC) and sphingomyelin, all of which are integral to the body. 
Acetylcholine is a neurotransmitter synthesized by cholinergic neurons [1]. 
Glycerophosphocholine and phosphocholine are major storage forms of choline in 
cytosol, while PC and sphingomyelin maintain membrane structure and integrity [1]. 
Sphingomyelin is also found in the myelin sheath surrounding nerve fibers. These 
choline metabolites are found in diet and/or derived from choline of dietary or 
endogenous origins. 
Although choline can be synthesized de novo, the body also relies on choline from 
food sources. The majority of dietary choline is comprised of PC, which is abundant in 
liver, eggs, meat and seafood [2]. Consumption of choline-deprived diet leads to 
increased signs of liver damage, the concern that is the basis of the Dietary Reference 
Intake for choline [3]. The Adequate Intake, established in 1998, recommends 550 
mg/day for adult men and 425 mg/day for women [3]. In addition to liver function, 
consumption of choline has been associated with favorable outcomes in in utero 
development, cognitive health, cardiovascular disease, and neurodegenerative 
diseases, among others [1,4].  
2 
Choline was recently linked to cardiovascular disease (CVD) as a precursor of 
trimethylamine-N-oxide (TMAO).  Using metabolomics approach, Wang et al. (2011) 
identified plasma choline and TMAO as predictors of CVD risk among patients 
undergoing elective cardiac evaluations [5]. The group further showed that 
atherosclerosis-prone mice (C57BL/6J Apoe-/-) supplemented with choline or TMAO 
had increased plasma TMAO concentrations, aortic atherosclerotic plaques and 
macrophage foam cell formation compared to chow-fed mice. Subsequent studies in 
rodents indicated that TMAO may promote atherosclerosis via increased cholesterol 
uptake by macrophage [5], decreased reverse cholesterol transport [6], enhanced 
platelet response [7] and prolonged hypertension [8]. 
Whether circulating TMAO is a cause of CVD and whether dietary choline 
contributes to CVD are currently debated. A systematic review of studies in cardiac 
and renal patients concluded that elevated TMAO concentrations were associated with 
increased risks for all-cause mortality and major adverse cardiovascular events [9]. On 
the other hand, another systematic review of prospective studies in general populations 
found no association between dietary choline and incident CVD [10]. This 
inconsistency may be indicative of other unknown factors and considerations in this 
diet—disease relationship. 
First, TMAO production from dietary choline requires other key metabolic factors. 
Upon consumption, unabsorbed dietary choline is metabolized by gut microbiota to 
trimethylamine [5], which is then absorbed via enterohepatic circulation and primarily 
oxidized to TMAO by hepatic flavin-containing monooxygenases (FMOs) [11]. Both 
FMOs and gut microbiota have been shown to influence pathways leading to insulin 
3 
resistance and atherosclerosis independently of TMAO [12,13]; this could account, at 
least in part, for the metabolic effect of TMAO. 
Second, TMAO is found abundantly in fish and seafood, which are recognized for 
their cardio-protective benefits [14]. In fact, levels of trimethylamine, a product of 
TMAO degradation in dead fish, is a universal indicator of fish spoilage [15]. It is 
unknown how fish consumption impacts circulating TMAO. Hypothetically, fish 
consumption could increase TMAO concentrations and, according to the proposed 
adverse effects of TMAO, would increase the risk of heart disease. This paradox 
suggests that TMAO may be a biomarker of other factors that in turn affect CVD risk, 
especially when most studies used dietary choline as a microbial-dependent source of 
TMAO. 
Third, the dietary choline/TMAO—CVD relationship may depend on the stage of 
the disease. Epidemiologic studies on TMAO and CVD endpoints were conducted in 
patients [9], while studies on dietary choline were population-based [10]. Similarly, 
mechanistic studies showing the contribution of TMAO to atherosclerosis must be 
conducted in disease-prone animal models due to their characteristics. Metabolic 
profiles of animals and humans with complications may also differ from those of their 
generally healthy counterparts. This difference could create an environment for an 
adverse dietary choline—disease association. Whether this association exists in a 
generally healthy population is unclear. 
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In summary, choline is a semi-essential nutrient that is speculated to contribute to 
CVD through the production of its metabolite TMAO. Current research findings are 
inconsistent, and key questions in the TMAO pathway remain unanswered.  
AIMS 
In this dissertation, the impact of dietary TMAO and its precursors (i.e., choline) on 
circulating TMAO is studied as well as how dietary TMAO is metabolized in healthy 
adults. We further investigate the relationship of choline intake with blood pressure as 
a proxy for CVD risk in a U.S. population. 
Aim I: (i) To quantify TMAO response to animal source foods among healthy men 
and (ii) to investigate how this response correlates with their gut microbiota 
composition.  
Aim II: (i) To quantitatively elucidate the metabolic fate of orally consumed 
TMAO in healthy men and (ii) to examine the effect of a polymorphism (G472A) in 
FMO isoform 3 coding gene on the metabolic fluxes of TMAO metabolites. 
Aim III: To assess the relationship of choline intake with both blood pressure and 
the prevalence odds of hypertension, using a cross-sectional National Health and 
Nutrition Examination Survey from 2007 to 2010. 
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TRIMETHYLAMINE-N-OXIDE (TMAO) RESPONSE TO ANIMAL SOURCE 
FOODS VARIES AMONG HEALTHY YOUNG MEN AND IS INFLUENCED BY 
THEIR GUT MICROBIOTA COMPOSITION: A RANDOMIZED CONTROLLED 
TRIAL 
Cho CE, Taesuwan S, Malysheva OV, Bender E, Tulchinsky NF, Yan J, et al. Mol Nutr 
Food Res 2017;61(1) 
 ABSTRACT 
Scope: Trimethylamine-N-oxide (TMAO), a metabolite linked to the gut 
microbiota, is associated with excess risk of heart disease. We hypothesized that: (i) 
TMAO response to animal source foods would vary among healthy men; and that (ii) 
this response would be modified by their gut microbiome.  
Methods and Results: A crossover feeding trial in healthy young men (n=40) was 
conducted with meals containing TMAO (fish), its dietary precursors, choline (eggs) 
and carnitine (beef), and a fruit control. Fish yielded higher circulating and urinary 
concentrations TMAO (46-62-times; P<0.0001), trimethylamine (8-14-times; 
P<0.0001) and dimethylamine (4-6-times; P<0.0001) than eggs, beef or the fruit 
control. Circulating TMAO concentrations were increased within 15-min of fish 
consumption suggesting that dietary TMAO can be absorbed without processing by 
gut microbes. Analysis of 16S rRNA genes indicated that high-TMAO producers 
8 
(≥20% increase in urinary TMAO in response to eggs and beef) had more Firmicutes 
than Bacteroidetes (P=0.04) and less gut microbiota diversity (P=0.03).  
Conclusion: Consumption of fish yielded substantially greater increases in 
circulating TMAO than eggs or beef. The higher Firmicutes to Bacteroidetes 
enrichment among men exhibiting a greater response to dietary TMAO precursor 
intake indicates that TMAO production is a function of individual differences in the 
gut microbiome. 
1.1 Introduction 
Trimethylamine-N-oxide (TMAO) is a naturally occurring small organic dietary 
compound that is abundant in fish, or can be generated from other nutrients including 
choline (abundant in eggs) and carnitine (abundant in beef). Upon consumption of 
foods containing TMAO or its dietary precursors (choline and carnitine), it is proposed 
that gut bacteria generate trimethylamine (TMA; volatile, fish-odor compound) [1] 
and to a lesser extent, dimethylamine (DMA) with subsequent absorption via 
enterohepatic circulation [2]. The majority of TMA is enzymatically converted to the 
odorless TMAO metabolite in a reversible reaction catalyzed by vitamin B2-
dependent flavin-containing monooxygenase 3 (FMO 3) in the liver. Loss-of-function 
mutations in this enzyme give rise to the rare genetic disorder known as 
trimethylaminuria or “the fish odor syndrome” [3]. Alternatively, TMA can be 
demethylated to DMA and methylamine (MA). 
9 
The significance of TMAO in physiologic processes received early attention due to 
its function as an osmolyte [4]. In addition, farmers recognized the benefits of adding 
TMAO to animal feed for the purposes of improving growth, carcass quality and 
nutrient digestibility [5]. More recently, TMAO has emerged as a predictive risk factor 
for heart disease in cardiac patients [6, 7] and colorectal cancer among post-
menopausal women [8]. However, very little is known about the effects of animal 
source foods on TMAO generation, absorption and elimination in healthy adults. 
Further, although there is an apparent role of the gut microbes in TMAO production, 
the gut microbiota composition in relation to TMAO production in humans has not 
been determined. 
Therefore, we aimed to test the hypotheses that: (i) TMAO response to animal 
source foods would vary among healthy men; and that (ii) this response would be 
modified by their gut microbiota composition. To achieve these aims, we conducted a 
crossover feeding trial whereby healthy young men consumed study meals of fish, 
eggs, meat and a fruit control in random order with one-week washout periods. TMAO 
biomarker response to the study meals was quantified in plasma and urine, while gut 
microbiota composition was assessed in feces. Because the FMO3 G472A genetic 
variant may adversely influence TMA conversion to TMAO [9], men were genotyped 
for this polymorphism, which was considered as a covariate in the statistical models.  
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1.2 Materials and methods 
1.2.1 Participants 
Healthy men (n = 40) aged 21-50 y with a body mass index (BMI) of 20-29.9 
kg/m2 were recruited by flyers posted around the Cornell University’s Ithaca campus 
and surrounding area from May to June 2014. A sample size of n = 40 was determined 
from a power analysis of a within-subject design to detect a 10% difference of plasma 
TMAO concentration at α < 0.05 and β = 0.8. Participants were screened by use of a 
blood chemistry profile, cell count and health history questionnaire. The exclusion 
criteria were men of age > 50 y, BMI ≥ 30 kg/m2, women, vegetarians, smokers and 
individuals with gastrointestinal diseases or complaints, chronic illnesses or other 
metabolic diseases (including trimethylaminuria), abnormal blood chemistry values 
indicative of organ dysfunctions, and those taking nutritional supplements, antibiotics 
or probiotics within 2 months of recruitment. Written informed consent was obtained 
from all participants, and the protocol was approved by the Institutional Review Board 
for Human Study Participants at Cornell University (Protocol ID#: 1403004534). This 
trial was registered at clinicaltrials.gov as NCT02558673. 
1.2.2 Study design 
A randomized, controlled crossover design with four arms comprised of study 
meals representing animal sources of TMAO and a fruit control was used in this study. 
Figure 1.1A depicts the participant flow throughout the study and the study design. 
The study meals were (i) eggs (3 whole hard-boiled; Wegmans); (ii) beef (6 ounces 
Philly-Gourmet Beef Patties, 100% Pure; Tops); (iii) fish (6 ounces cod fillet; Tops)]  
11 
 
Figure 1.1 A schematic of the participant flow throughout the study and the study design (A) 
and the study protocol (B) 
and (iv) the fruit control (2 single-serve packages of Mott’s natural applesauce; Tops), 
and were administered in commonly consumed servings. The order of study meals for 
each participant was assigned by a study investigator using random number generator 
(random.org), and each meal was administered in a single day separated by a 1-week 
washout period. All meals were prepared in the Human Metabolic Research Unit 
(HMRU) kitchen at Cornell University on the morning of testing. 
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1.2.3 Protocol 
The study procedure is illustrated in Figure 1.1B. After an overnight fast (10-h), 
participants arrived at the HMRU between 0700 and 1000 for each of the four visits. 
The day prior to the study session, participants were advised to avoid consumption of 
grapefruit juice and indole-containing vegetables (i.e., broccoli, Brussel sprouts, 
cabbage, cauliflower, kale and bok choy) as these foods can decrease FMO3 enzyme 
activity and alter TMAO metabolism [2]. Participants were also asked to maintain 
their normal routine, including exercise, and eat a similar meal the night before each 
of the four sessions.  
At the beginning of each session, participants completed a 24-h dietary recall to 
assess compliance to the grapefruit juice and indole food restriction. If participants 
reported consumption of these foods, or significant deviations from their normal 
routine, the session was rescheduled. A baseline blood sample was obtained by a 
phlebotomist using a standard venipuncture procedure, and participants collected their 
baseline urine sample.  
Participants then consumed a randomly allocated study meal with one cup of water 
within a 15-min period. Following the consumption of the study meal, serial blood 
samples were obtained at 15, 30-min, 1, 2, 4 and 6-h, and each participant collected 
their urine samples into bottles throughout the 6-h study period which were 
subsequently pooled. At 4.5-h, participants were provided a fixed snack (i.e., 
applesauce) and water. Throughout each study session, participants refrained from 
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eating and drinking foods and beverages (other than water) outside those provided by 
study personnel. 
1.2.4 Sample collection 
At the screening visit, fasting serum and whole blood were obtained for blood 
chemistry profiles and complete cell counts, respectively, using a previously described 
method [10]. During the feeding trials, plasma and buffy coat were obtained for 
metabolite measurements [11, 12] and FMO3 G472A (rs 2266782) genotyping.  
Urine was self-collected in wide-mouth specimen containers (120 mL; Thermo 
Scientific) at study-baseline, and in wide-mouth polyethylene bottles (1 L; Nalgene) 
during the 6-h period, and kept on ice. Urine volumes were recorded separately for 
study-baseline and the 6-h study period. In addition, prior to consumption of the fruit 
control, participants collected stool (complete bowel movement) in a bag provided by 
study personnel, and delivered to the HMRU in a thermo-insulated bag with ice packs. 
All samples were de-identified, distributed among several storage vials and stored at -
80 °C for further analyses. 
1.2.5 Analytical methodology 
1.2.5.1 Blood chemistry profiles and complete cell counts 
High-density lipoprotein (HDL), low-density lipoprotein (LDL), lipids, protein, 
creatinine (Cr), bilirubin, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl 
transpeptidase (GGT) and blood urea nitrogen (BUN) concentrations were measured 
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in serum collected at screening by the Dimension Xpand chemistry analyzer (Siemens 
Healthcare Diagnostic). 
White blood cells (WBC), lymphocytes, monocytes, granulocytes and red blood 
cells (RBC) were measured in whole blood collected at screening by the Act diff 2 
hematology analyzer (Beckman Coulter). 
1.2.5.2 TMAO metabolite measurements 
TMAO, TMA, DMA and MA were measured in plasma, urine and study meals by 
liquid chromatography (LC)-tandem mass spectrometry MS/MS as described by 
Johnson et al. [13] with modifications to measure all of the methylamine metabolites 
in a single run. Samples were run in batches with each batch containing all time points 
and study meals. Study meal total choline (sum of free choline, 
glycerophosphocholine, phosphocholine, phosphatidylcholine, sphingomyelin), 
betaine and carnitine contents were quantified by the methods of Koc et al. [14] and 
Holm et al. [15] with modifications [16]. All meals were quantified in a single run. 
1.2.5.2.1 Sample preparation 
For plasma metabolites, 100 µL plasma was mixed with 200 µL acetonitrile (ACN) 
and 10 µL internal standard, and centrifuged at 20,817 x g for 5 min at room 
temperature. Stock solutions for the internal standard were prepared by mixing d3-MA 
hydrochloride (Sigma-Aldrich), d6-DMA hydrochloride (Sigma-Aldrich), NG-methyl-
L-arginine acetate (Sigma-Aldrich), 13C3-TMA hydrochloride (Isotec), d3-betaine 
ammonium chloride (CDN Isotopes), L-carnitine-d3 hydrochloride (CDN Isotopes), 
d13-choline chloride (CDN Isotopes), 13C3-TMAO (Toronto Research Chemicals Inc), 
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methyl-13C L-methionine (Cambridge Isotope Laboratories) in methanol:water (1:1). 
The supernatant was transferred to a vial with a disposable glass insert and 2 µL 
concentrated NH4OH and 30 µL ethyl bromoacetate (EBA; 20 mg/mL in ACN) were 
added. After incubation at room temperature for 45 min, the solution was diluted 1:1 
with a mixture of water:ACN:CH2O2 (1:1:0.0005) prior to injection into the LC-
MS/MS system. The calibration points were prepared from stock solutions to yield the 
following final concentrations (all in nmol/mL): TMAO (0.04-400), TMA (0.002-0.3), 
DMA and choline (0.2-30), betaine (0.4-200), carnitine (0.2-200).  
For urine metabolites, 50 µL urine was mixed with 10 µL internal standard, 2 µL 
concentrated NH4OH and 60 µL EBA (20 mg/mL in ACN). After incubation at room 
temperature for 45 min, the solution was diluted 7:1 with a mixture of 
water:ACN:CH2O2 (1:1:0.0005) and injected into the LC-MS/MS system. The 
calibration points were prepared from stock solutions to yield the following final 
concentrations (all in nmol/mL): TMAO and DMA (40-8000), TMA (0.1-20), MA (2-
400), and choline, betaine and carnitine (2-400). Metabolite concentrations in urine 
were adjusted for Cr, which was measured using the Dimension Xpand chemistry 
analyzer (Siemens Healthcare Diagnostic) in the Human Nutritional Chemistry 
Service Laboratory at Cornell University.  
For food, 40 mg food homogenate (study meal homogenized in 0.1 M sterilized 
potassium phosphate buffer) was mixed with 150 µL of 0.1% CH2O2 in ACN and 10 
µL of internal standard. The mix was centrifuged at 20,817 x g for 10 min at 4 °C 
followed by transfer of the supernatant into a vial with a disposable glass insert. 
Concentrated NH4OH (2 µL) and 30 µL EBA were added to the supernatant and 
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incubated at room temperature for 45 min. The solution was then diluted 1:1 with a 
mixture of water:ACN:CH2O2 (1:1:0.0005) prior to injection into the LC-MS/MS 
system. The calibration points were prepared from stock solutions to yield the 
following final concentrations (all in nmol/extract): TMAO, betaine and carnitine (0.3-
80), TMA and DMA (0.15-40), MA (0.75-200) and choline (1.5-400). 
1.2.5.2.2 LC-MS/MS Analyses 
Metabolites in urine and study meals were measured using the Accela HPLC 
system TSQ Quantum Access mass spectrometer (ThermoElectron Corp), while those 
in plasma were measured using the Surveyor HPLC system TSQ Quantum Ultra mass 
spectrometer. The injection volume was 10 µL, and the column and autosampler 
temperatures were at 25°C and 5 °C, respectively. Metabolites were separated on a 
Prevail silica column (150 x 2.1 mm, 5 µm; Grace) with a matching guard column (7.5 
x 2.1 mm, 5 µm). The mobile phase consisted of ACN and 0.1% formic acid in 0.15 
mmol/L ammonium acetate in water (CH2O2-NH4OAc) with the following gradient: 
81% ACN, 19% CH2O2-NH4OAc at 0 min with a flow rate of 200 µL/min, 81% ACN, 
19% CH2O2-NH4OAc at 8 min with a flow rate of 500 µL/min, then linear gradient to 
65% ACN, 35% CH2O2-NH4OAc at 10 min with a flow rate of 500 µL/min, 65% 
ACN, 35% CH2O2-NH4OAc at 13 min with a flow rate of 400 µL/min, then from 13 
to 15-min linear gradient back to 81% ACN, 19% CH2O2-NH4OAc, and from 15 to 20 
min the column was equilibrated to original conditions with a flow rate of 500 
µL/min.  
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Electrospray ionization in the positive ion mode and multiple-reaction monitoring 
were used to detect the following transitions: m/z 76.3  58.4 for TMAO and m/z 
162.1  60.1 for carnitine. TMA, DMA and MA were derivatized with EBA and the 
transitions were as follows: m/z 146.1  118.1 for TMA-EBA, m/z 132.1  58.1 for 
DMA-EBA and m/z 118.1  44.3 for MA-EBA.  
Metabolite and food concentrations were determined relative to standard curves 
which were prepared by mixing various amounts of TMAO, TMA, DMA and MA 
with water. The intra-assay CV for plasma and urine was 2% and 1% for TMAO, 17% 
and 4% for TMA, 2% and 2% for DMA, and ND and 8% for MA, whereas the inter-
assay CV for plasma and urine was 6% and 5% for TMAO, 38% and 8% for TMA, 
6% and 6% for DMA, and ND and 49% for MA based on in-house control duplicates 
(n = 3 with differing TMAO concentrations for plasma; n = 2 with differing TMAO 
concentrations for urine). The relatively low precision for TMA and MA represents the 
volatility and/or low abundance of these compounds.  
1.2.5.3 Genotyping 
DNA was extracted according to the manufacturer’s protocol (DNeasy Tissue kit, 
Qiagen) from buffy coat. The FMO3 G472A (rs 2266782) variant [9] was determined 
using a commercially available fluorescent Taqman probe kit (ThermoFisher 
Scientific) on the LightCycler® 480 real-time RT-PCR instrument (Roche) as 
previously described [17]. 
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1.2.5.4 16S rRNA gene sequencing  
Genomic DNA was extracted from ~100 mg of stool using the PowerSoil High-
Throughput DNA Isolation Kit (MoBio Laboratories) with bead beating according to 
the manufacturer’s protocol. Bacterial 16S rRNA genes were PCR amplified for the 
V4 hypervariable region using the 515F and 806R primers as previously described 
[18] and sequences found at the Earth Microbiome Project 
(http://www.earthmicrobiome.org/emp-standard-protocols/16s/). PCR reactions 
consisted of Hot Master PCR mix (Five Prime), 10-100 ng DNA template and 10 µM 
of each primer, with initial denaturation at 94 °C for 3 min followed by 25 cycles of 
denaturation at 94 °C for 45 s, annealing at 50 °C for 60 s, extension at 72 °C for 90 s, 
and final extension at 72 °C for 10 min. Duplicate PCR reactions were performed for 
each sample, and were combined and purified using magnetic beads (Mag-Bind 
EZPure, Omega Bio-Tek). Purified PCR amplicons were quantified using the Quant-iT 
PicoGreen dsDNA Assay Kit (Invitrogen). Amplicons were then combined into a 
single tube with a final concentration of 11 ng/µL. Of the 40 stool samples, 5 samples 
failed to amplify, thus 35 samples of DNA were sequenced paired-end on the Illumina 
MiSeq platform at Cornell Biotechnology Resource Center Genomics Facility. 
1.2.6 16S rRNA gene sequence analyses 
Matching paired-end sequences were merged using the fastq-join command and 
demultiplexed in the open-source software package Quantitative Insights Into 
Microbial Ecology (QIIME) version 1.8.0 [19]. Quality filtering removed sequences 
containing low-quality reads (Phred quality score ≤ 25), ambiguous bases, primer 
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mismatches, uncorrectable barcodes and lengths < 200 bp. Of the 35 sequenced 
samples, 9 samples did not meet the quality control filtering, therefore 26 samples 
were used for the gut microbiome analyses. De novo operational taxonomic unit 
(OTU) picking was performed using the UCLUST algorithm. Representative OTU 
sequences were aligned using PyNAST with 80% identity and were taxonomically 
classified using Ribosomal Database Project (RDP) classifier at 97% identity. A 
phylogenetic tree was built using FastTree. Rarefaction was performed at 60,000 
sequences per sample to calculate α-diversity (within sample diversity) using Faith’s 
phylogenetic diversity, Chao 1 and Observed Species, as well as jack-knifed β-
diversity (between sample diversity) using the unweighted UniFrac distance matrices 
for principal coordinates analysis (PCoA). A heatmap was created from the log 
abundance of all genera using the R package. 
1.2.7 Statistical analyses 
Statistical analyses were conducted in SAS (Version 9.3, SAS Institute). Two-way 
repeated measures analysis of variance (ANOVA) using the PROC MIXED model 
procedure determined the effect of study meal, time and study meal-by-time 
interaction on metabolite concentrations in plasma and urine. The covariates, age, 
BMI, study session order and genotype (FMO3 G472A), that did not reach a 
significance of P ≤ 0.05 were removed from the model in a stepwise manner. A 
significant interaction effect was followed by one-way repeated measures ANOVA and 
Tukey-Kramer post-hoc test. Participants were categorized as high-TMAO producers 
or low-TMAO producers based on the median excretion of TMAO (20%) following 
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the consumption of the egg and beef meals. After sample sequencing and data quality 
filtering, the gut microbiota composition was compared between high-TMAO 
producers (n = 11) and low-TMAO producers (n = 15) using False Discovery Rate 
(FDR)-corrected ANOVA and nonparametric anosim statistical method within QIIME.  
Unpaired t-test was used to assess differences in the baseline characteristics of the 
TMAO response groups. Significant differences were reported at P < 0.05 with a FDR 
at 95%. All data are expressed as means ± SEM.  
1.3 Results 
1.3.1 Participant characteristics and baseline metabolite concentrations 
Forty healthy men had a mean age of 27.8 ± 1.0 y, BMI of 24.2 ± 0.4 kg/m2, and 
serum blood chemistry and blood cell counts within the normal range (Table 1.1). 
Thirty-five percent of the participants were homozygous wild-type GG genotype for 
FMO3 G472A, 55% were heterozygous GA and 10% were homozygous variant AA, 
which is consistent with the distribution observed in the general population [20]. 
TMAO and its derivatives did not differ across study meals. 
1.3.2 Study meal TMAO content (see Table 1.2) 
1.3.2.1 TMAO and its derivatives 
The fish meal contained 650 times more TMAO, 200 times more TMA and 1600 
times more DMA compared to the egg and beef meals (P < 0.0001), whereas the fruit 
did not show any detectable levels of these metabolites. Food MA did not differ 
among the study meals. Total choline concentration was 125 times higher in eggs and 
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Table 1.1 Participant characteristics and baseline measures for all participants 
(n = 40).  
Participant Characteristics 
Age (y) 27.8 ± 1.0 
BMI (kg/m2) 24.2 ± 0.4 
Genotype 
 GG % 35 
GA % 55 
AA % 10 
  Blood Chemistry Concentrations (all serum) 
HDL (mg/dL) 55 ± 2 
LDL (mg/dL) 117 ± 5 
Cholesterol (mg/dL) 170 ± 6 
Triglycerides (mg/dL) 67 ± 5 
Total bilirubin (mg/dL) 0.8 ± 0.0 
Direct bilirubin (mg/dL) 0.2 ± 0.0 
ALP (U/L) 75 ± 3 
Cr (mg/dL) 1.1 ± 0.0 
CK (U/L) 156 ± 10 
LDH (U/L) 157 ± 3 
Amylase (U/L) 57 ± 3 
Lipase (U/L) 157 ± 8 
AST (U/L) 21 ± 1 
ALT (U/L) 33 ± 2 
GGT (U/L) 32 ± 2 
Total protein (g/dL) 7.6 ± 0.1 
Albumin (g/dL) 4.3 ± 0.0 
BUN (mg/dL) 15 ± 1 
  Cell Counts 
 WBC (×103/µL) 5.6 ± 0.2 
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Lymphocytes (×103/µL) 1.9 ± 0.1 
Monocytes (×103/µL) 0.2 ± 0.0 
Granulocytes (×103/µL) 3.5 ± 0.2 
RBC (×103/µL) 5.2 ± 0.1 
  TMAO (nmol/mL) 3.3 ± 0.2 
TMA (pmol/mL) 18.1 ± 0.8 
DMA (nmol/mL) 1.9 ± 0.0 
MA (nmol/mL) ND 
  Urinary Methylamine Excretion 
TMAO (nmol/mmol Cr) 26.6 ± 1.0 
TMA (nmol/mmol Cr) 0.1 ± 0.0 
DMA (nmol/mmol Cr) 27.0 ± 0.3 
MA (nmol/mmol Cr) 4.2 ± 0.4 
  
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; ALP, alkaline phosphatase; Cr, creatinine; CK, creatine kinase; LDH, lactate 
dehydrogenase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, 
gamma-glutamyl transpeptidase; BUN, blood urea nitrogen; WBC, white blood cell; RBC, red 
blood cell; TMAO,  trimethylamine-N-oxide; TMA, trimethylamine; DMA, dimethylamine; 
MA, methylamine. Baseline plasma and urine levels (averaged across all four sessions) of 
TMAO and methylamine derivatives TMA, DMA and MA. ND denotes not detectable. 
Urinary concentrations were adjusted by urinary Cr. Values are mean ± SEM, n = 40. 
38 times higher in beef and fish (P < 0.0001) compared to the fruit control. Food 
betaine content was 27 times higher in beef and fish compared to egg and fruit meals 
(P < 0.0001). Carnitine was highest (P < 0.0001) in beef followed by fish and then 
eggs, and was not detected in the fruit control.  
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Table 1.2 Food concentrations of trimethylamine-N-oxide (TMAO) and methylamine 
derivatives trimethylamine (TMA), dimethylamine (DMA) and methylamine (MA) as well as 
total choline (sum of free choline, glycerophosphocholine, phosphocholine, 
phosphatidylcholine, sphingomyelin), betaine and carnitine in egg, beef, fish and fruit study 
meals. ND denotes not detectable. Values within rows with different letter superscripts are 
significantly different by one-way ANOVA, Tukey-Kramer post-hoc test. NS denotes not 
significant. Values are mean ± SEM, each meal with 5 replicates. 
Food content 
(mg) Fruit Egg Beef Fish P value 
TMAO - 0.8 ± 0.1a 0.9 ± 0.1a 528.9 ± 9.4b < 0.0001 
TMA - 0.0 ± 0.0a 0.1 ± 0.0a 5.1 ± 0.7b < 0.0001 
DMA - 0.0 ± 0.0a 0.0 ± 0.0a 58.5 ± 0.2b < 0.0001 
MA - 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.0 NS 
Total Choline 3.8 ± 0.1a 478.8 ± 15.7c 132.3 ± 7.0b 161.2 ± 0.6b < 0.0001 
Carnitine - 0.0 ± 0.0a 71.0 ± 3.0c 7.5 ± 0.3b < 0.0001 
Betaine 0.0 ± 0.0a 0.9 ± 0.0a 12.7 ± 0.3b 12.4 ± 0.2b < 0.0001 
 
1.3.3 TMAO biomarker response to the study meals 
1.3.3.1 Circulating concentrations of TMAO and methylamine derivatives 
Study meal and time interacted (P < 0.0001) to influence plasma concentrations of 
TMAO and its methylamine derivatives (Figure 1.2). As compared to egg, beef and 
fruit control, fish consumption yielded plasma concentrations that were 48-62 times  
higher for TMAO (P < 0.0001), 8-14 times higher for TMA (P < 0.0001) and 4-5 times  
higher for DMA (P < 0.0001), all of which peaked at 2-h and remained elevated until 
the end of the 6-h study period. MA concentrations were not detectable in plasma. The  
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Figure 1.2  Effects of the study meals on plasma concentrations of trimethylamine-N-oxide 
(TMAO) (A), trimethylamine (TMA) (B) and dimethylamine (DMA) (C) across 
the 6-h study period. Different letter superscripts show a significant effect of 
study meal at each time point (one-way ANOVA, Tukey-Kramer post-hoc test). 
Values are mean ± SEM, n = 40 per study meal. 
effect of FMO3 G472A on TMAO biomarker response was significant therefore this 
genotype was used as a covariate. 
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Similar to plasma levels, study meal interacted with time (P < 0.005) to influence 
urinary TMAO and methylamine derivative concentrations (Table 1.3). As compared 
to egg, beef and fruit control, fish consumption resulted in urinary excretions that were 
46-51 times higher for TMAO (P < 0.0001), 9-12 times higher for TMA (P < 0.0001) 
and 6 times higher for DMA (P < 0.0001) as compared to egg, beef and fruit control 
during the 6-h study period (P < 0.0001).  
Because of the substantial TMAO response following consumption of the fish 
study meal, we were unable to detect differences in TMAO response among the egg, 
beef and fruit study meals. Thus, we assessed TMAO response for eggs, beef and fruit 
separately from fish, and compared the response to study-baseline (Figure 1.3). A 
greater increase in plasma TMAO at each time point was detected for eggs and beef 
compared to the fruit control (P < 0.05). Likewise, the change in urinary TMAO 
excretion across the 6-h study period was greater following the consumption of eggs 
and beef compared to the fruit control (P = 0.03).  
Notably, the individual variations in urinary TMAO response after the consumption 
of eggs and beef ranged from -30% to 270% (Figure 1.4). We therefore stratified our 
participants into high-TMAO producers (n = 11; those with ≥20% i ncrease in urinary 
TMAO in response to eggs and beef) versus low-TMAO producers (n = 15; those with 
<20% increase in urinary TMAO in response to eggs and beef) for the microbiome 
analyses (see next section).  We also assessed for differences in the baseline 
characteristics of the TMAO response groups but none were detected (see 
Supplementary Table 1.1). 
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Table 1.3 Effects of the study meals on urinary concentrations of trimethylamine-N-oxide 
(TMAO) and the methylamine derivatives trimethylamine (TMA), dimethylamine (DMA) and 
methylamine (MA) adjusted for creatinine (Cr) at study-baseline (0 min) and across the 6-h 
study period. Two-way ANOVA showed a significant study meal-by-time interaction (P < 
0.005). One-way ANOVA, Tukey-Kramer post-hoc test showed a significant effect of diet for 
pooled study urine across 6-h indicated by different letter superscripts. NS denotes not 
significant. Values are mean ± SEM, n = 40 per study meal. 
(nmol/mmol 
Cr in urine) 
Fruit Egg Beef Fish P value 
TMAO 
     0 min 28.4 ± 2.1 24.5 ± 1.9 26.0 ± 2.5 27.9 ± 1.8 NS 
Study (0-6 h) 29.0 ± 1.8a 32.2 ± 2.7a 31.9 ± 3.0a 1486.9 ± 57.4b P < 0.0001 
TMA      
0 min 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 NS 
Study (0-6 h) 0.2 ± 0.1a 0.1 ± 0.0a 0.1 ± 0.0a 1.7 ± 0.6b P < 0.0001 
DMA      
0 min 27 ± 1 27 ± 1 27 ± 1 27 ± 1 NS 
Study (0-6 h) 30 ± 1a 31 ± 1a 28 ± 1a 180 ± 9b P < 0.0001 
MA      
0 min 3.8 ± 0.5 3.3 ± 0.4 5.5 ± 1.2 4.0 ± 0.4 NS 
Study (0-6 h) 4.6 ± 0.4 6.2 ± 0.8 5.9 ± 0.7 6.2 ± 0.6 NS 
 
1.3.4 Gut microbiota composition 
To address whether microbiota composition was a determinant of TMAO response, 
we obtained a one-time baseline stool sample from each participant. Of the 40 stool 
samples, 26 samples were used in the analyses after amplification and quality control 
yielding 6,770,441 high-quality gene sequences with average sequences lengths (mean 
± standard deviation) of 254 ± 10.  High-TMAO producers had lower α-diversity  
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(within-individual) measure than low-TMAO producers (P = 0.03 with 999 
permutations by Monte carlo method; Figure 1.5). PCoA analysis of the unweighted 
UniFrac distances and relative abundance of the bacteria showed distinct bacterial 
profiles between low-TMAO producers and high-TMAO producers (P = 0.04, R2 = 
0.11 with 999 permutations by anosim method; Figure 1.6).  
We then visualized gut microbiota differences between high-TMAO producers and 
low-TMAO producers using a heatmap (Figure 1.7). A table of representative OTUs 
is included as Supplementary Table 1.2 
(https://onlinelibrary.wiley.com/doi/10.1002/mnfr.201600324). High-TMAO 
producers had 58.1% Firmicutes to 32.6% Bacteroidetes (~2:1 
Firmicutes:Bacteroidetes) whereas low-TMAO producers had 47.7% Firmicutes to  
Figure 1.3  Effects of the study meals (eggs, beef and fruit only) on trimethylamine-N-oxide 
(TMAO) concentrations in serially-collected plasma across time (A) and pooled 
urine (B). Data are expressed as changes from study-baseline (0 min). Different 
letter superscripts show a significant effect of study meal (one-way ANOVA, 
Tukey-Kramer post-hoc test). Values are mean ± SEM, n = 40 per study meal. 
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Figure 1.4  Percent variation of urinary trimethylamine-N-oxide (TMAO) concentration after 
the consumption of egg and beef study meals. The urinary TMAO response was 
averaged between egg and beef consumption. The variation ranged from -30% to 
270% among individuals. The participants were stratified into high-TMAO 
producers (n = 11) shown as black circles and defined as having ≥20% increase 
in urinary TMAO concentrations after egg and beef consumption, versus low-
TMAO producers (n = 15) in white circles and defined as having <20% increase 
in urinary TMAO concentrations. 
47.2% Bacteroidetes (1:1 Firmicutes:Bacteroidetes). High-TMAO producers were 
represented by Clostridiales within the Firmicutes phylum of which were 
Bacteroidaceae and Prevotellaceae. The Archaea phylum was represented in the low-
TMAO producers but absent in the high-TMAO producers. 
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Figure 1.5  Within-individual difference shown as box-plots (mean ± standard deviation) for 
the 16S rRNA sequence data from baseline stool samples of healthy male 
participants (n = 26). Alpha diversity metrics were computed for rarefied 
operational taxonomic unit (OTU) at maximum sampling depth of 60,000 
sequences per sample. High-trimethylamine-N-oxide (TMAO) producers (n = 11) 
were defined as having ≥20% increase in urinary TMAO concentrations after egg 
and beef consumption, whereas low-TMAO producers (n = 15) were defined as 
having <20% increase in urinary TMAO concentrations. P = 0.03 with 999 
permutations by Monte carlo method. 
1.4 Discussion 
This study sought to advance understanding of the effects of animal source foods 
on TMAO production, and to determine whether this response was influenced by an 
individual’s gut microbiome. Three main findings emerged: (i) fish consumption 
yielded several-fold higher quantities of TMAO metabolites than either eggs or beef;  
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Figure 1.6  Principal coordinates analysis (PCoA) of the unweighted UniFrac distances for 
the 16S rRNA sequence data from baseline stool samples of healthy male 
participants (n = 26). Beta diversity metrics (between-individual differences) 
were jackknifed by repeatedly re-sampling at 60,000 sequences per sample. Axes 
show the percent variation explained by the principal components (PCs). High-
trimethylamine-N-oxide (TMAO) producers (n = 11) were defined as having 
≥20% increase in urinary TMAO concentrations after egg and beef consumption, 
whereas low-TMAO producers (n = 15) were defined as having <20% increase in 
urinary TMAO concentrations. The size of the symbols indicates operational 
taxonomic unit (OTU) clustering in the microbiomes with red points representing 
those from high-TMAO producers and the blue points from low-TMAO 
producers. A distinct grouping of the gut microbiota profiles is indicated by the 
red triangle outline for high-TMAO producers versus the blue triangle outline for 
low-TMAO producers. P = 0.04, R2 = 0.11 with 999 permutations by anosim 
method. 
(ii) dietary TMAO can be absorbed intact without processing by gut microbes; and 
(iii) high-TMAO producers (≥20% increase in urinary TMAO in response to eggs and 
beef) had more Firmicutes than Bacteroidetes and a less diverse gut microbiome. 
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Figure 1.7  Heatmap of relative operational taxonomic unit (OTU) abundances for the 16S 
rRNA sequence data from baseline stool samples of male participants (n = 26) to 
differentiate between high-trimethylamine-N-oxide (TMAO) producers (n = 11; 
those having ≥20% increase in urinary TMAO concentrations after egg and beef 
consumption) versus low-TMAO producers (n = 15; those having <20% increase 
in urinary TMAO concentrations). The taxonomic assignment of each OTU 
represents the gut microbiota at the genus level which is grouped into the phylum 
level as indicated with black square brackets. The color key corresponds to 
percent relative abundance of the gut microbiota of OTU at each expression 
level. 
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1.4.1 Fish consumption yields the highest concentrations of plasma and urinary 
TMAO concentrations compared to all other study meals 
Fish consumption yielded ~50 times higher circulating concentrations of TMAO 
than either eggs or beef which is consistent with previous reports of substantially 
higher urinary TMAO concentrations [21, 22] following the consumption of fish 
compared to meat, dairy, fruits, vegetables or grain. Notably, plasma TMAO was 
elevated within 15 minutes of fish consumption indicating that the absorption of 
dietary TMAO may occur without processing to TMA by the gut microbes as 
previously proposed [23]. The sustained elevation in circulating TMAO in response to 
fish consumption, despite substantial urinary excretion, suggests that a portion of the 
TMAO is retained by the body possibly due to its functions as an osmolyte [4] and 
protein stabilizer [24]. Other methylamine derivatives influenced by diet, albeit to a 
lesser extent than TMAO, included TMA and DMA, both of which showed higher 
levels in response to fish versus eggs and beef. 
In light of the recent proposed role of TMAO as a causative agent for 
cardiovascular disease [7, 23], and a recent report of higher serum TMAO 
concentrations and accelerated aortic plaque formation in apoE null mice with 
increased fish intake [25], some researchers have advocated for the restriction of 
animal source foods that raise circulating TMAO concentrations [7]. However, these 
animal source foods are enriched in nutrients that are required for optimal health [26], 
and fish consumption is well-known for its cardio-protective attributes in humans [27]. 
Moreover, circulating TMAO and carnitine concentrations were inversely associated 
or showed no association with the development of chronic diseases [28, 29]. Thus, 
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caution is warranted when proposing dietary recommendations that restrict the intakes 
of animal source foods because of their TMAO-raising characteristics. 
1.4.2 TMAO response to dietary precursors may be a biomarker of the gut 
microbiota composition 
Gut microbes are known to participate in modulating TMAO response to its dietary 
precursors and potentially chronic disease susceptibility [6, 23, 30]. However, TMAO 
response is highly variable and it is unclear whether this variation arises from 
individual differences in gut microbiota composition. To address this question, we 
used urinary TMAO excretion to stratify our participants into “high” (≥20% increase) 
or “low” (<20% increase) TMAO producers, and examined differences in the gut 
microbiota composition between the two groups. 
Although differences in the gut microbiota were subtle at the individual OTU level, 
high-TMAO producers were characterized by enriched ratios of Firmicutes to 
Bacteroidetes compared to low-TMAO producers (Figure 1.4), which is consistent 
with previous reports that TMAO production potential is detected in Firmicutes but 
absent in Bacteroidetes [31]. Furthermore, low-TMAO producers had more archaea 
Methanobrevibacter, which has been proposed to deplete host TMA levels [32]. Lower 
α- diversity (within-individual difference) was also observed among high-TMAO 
producers indicating that TMAO production may be driven by a select set of bacteria 
(e.g., Firmicutes).  
Distinct gut microbiota profiles between high-TMAO compared to low-TMAO 
producers in response to its dietary precursors indicate that circulating TMAO may be 
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a biomarker of the gut microbiota. As such, higher circulating concentrations of 
TMAO in a disease versus non-disease state may reflect differences in gut microbe 
composition, rather than indicating a causative role of TMAO in the disease process. A 
greater ratio of Firmicutes to Bacteroidetes has previously been associated with 
increased risk of obesity and metabolic syndrome [33], and this gut microbiota 
characterization may also be linked to atherosclerosis-associated dysbiosis. The 
significance of these findings is that circulating TMAO may be used to identify 
individuals with microbiota profiles that increase disease susceptibility, and thereby 
inform the development of dietary and pharmaceutical strategies aimed at increasing 
gut microbiota diversity and restoring the symbiotic relationship between the gut 
microbes and their host.  
1.5 Study limitations and future directions 
This was a short-term feeding study that focused on advancing current 
understanding of TMAO metabolism in healthy male adults. As such, the findings may 
not reflect long-term effects of the diet and may not be generalizable to other segments 
of the population including women and those with health conditions. In addition, pre-
disease clinical endpoints, such as markers of inflammation, were not evaluated.  More 
studies are needed to address these important issues and evaluate the clinical utility of 
lowering circulating concentrations of TMAO as a means to improve human health. 
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1.6 Conclusion 
Consumption of fish, which is high in TMAO, yielded substantially greater 
increases in circulating TMAO than eggs or beef, which contain high amounts of 
dietary TMAO precursors. The rapid rise in circulating TMAO in response to fish 
consumption demonstrated that the absorption of intact dietary TMAO occurs in a 
manner that is independent of the gut microbes. The higher Firmicutes to 
Bacteroidetes microbial enrichment among men exhibiting greater response to dietary 
TMAO precursor intake indicates that circulating TMAO can reflect a person’s 
microbiota which may in turn modulate their risk of disease. 
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ABSTRACT 
Trimethylamine-N-oxide (TMAO) is associated with chronic disease risk. 
However, little is known about the metabolic fate of dietary TMAO. This study sought 
to quantitatively elucidate the metabolic fate of orally consumed TMAO in humans. 
As part of a crossover feeding study, healthy young men (n = 40) consumed 50 mg 
deuterium-labeled methyl d9-TMAO (d9-TMAO), and enrichments of TMAO and its 
derivatives were measured in blood for 6 h, urine and stool, as well as skeletal muscle 
in a subset of men (n = 6). Plasma d9-TMAO was detected as early as 15 min, 
increased until 1 h, and remained elevated through the 6-h period. TMAO exhibited an 
estimated turnover time of 5.3 h, and ~96% of the dose was eliminated in urine by 24-
h, mainly as d9-TMAO. No d9-TMAO was detected in feces. Notably, d9-TMAO and 
d9-trimethylamine were detected in skeletal muscle (n = 6) at 6-h, and the enrichment 
ratio of d9-TMAO to d9-trimethylamine was associated with a genetic variant in 
flavin-containing monooxygenase isoform 3 (FMO3 G472A). These results suggest 
that the absorption of orally consumed TMAO is near complete and may not require 
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processing by gut microbes. TMAO exhibits fast turnover in the circulation with the 
majority being eliminated in urine within 24-h. A small portion of the dose, however, 
is taken up by extrahepatic tissue in a manner that is associated with FMO3 G472A 
polymorphism. This trial was registered at clinicaltrials.gov as NCT02558673. 
2.1 Introduction 
Elevated circulating concentrations of trimethylamine-N-oxide (TMAO) have been 
linked to increased risk of chronic kidney disease [1,2] greater development and 
progression of cardiovascular disease [1,3,4] and higher risk of colorectal cancer 
among post-menopausal women [5]. TMAO is derived from consumption of choline 
(abundant in eggs) and L-carnitine (abundant in red meat) [4,6]. Dietary choline and 
L-carnitine are metabolized by gut microbiota to trimethylamine (TMA) [4,6] and 
possibly to small amounts of dimethylamine (DMA) and methylamine (MA) [7,8]. 
These methylamines are absorbed via enterohepatic circulation, and TMA is primarily 
oxidized to TMAO by hepatic flavin-containing monooxygenases (FMOs) [9]. TMAO 
and its derivatives are then released into systemic circulation and suggested to be 
excreted in urine [10,11].  
Interestingly, fish and seafood, which are recognized for their cardio-protective 
benefits [12], are the richest food sources of TMAO [10]. Results from our recent 
crossover feeding trial showed that fish consumption increased post-prandial plasma 
and urinary TMAO concentrations over 50 times more than eggs or beef [13]. This 
increase underscores the substantial impact of dietary TMAO on circulating TMAO 
concentrations.  In spite of this, the metabolism of dietary TMAO in humans is poorly 
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understood, although it has been purported to enter the same metabolic pathway as its 
precursors [14].  
To quantitatively elucidate the metabolic fate of orally consumed TMAO, the 
current study employed stable isotope methodology using deuterium-labeled methyl 
d9-TMAO (d9-TMAO) in 40 healthy men.  Enrichments of d9-TMAO, along with its 
methylamine derivatives, were measured in blood, skeletal muscle, urine and stool. 
The association of a polymorphism (G472A) in FMO isoform 3 coding gene (FMO3) 
with the metabolic fluxes of labeled TMAO metabolites was also examined.  
2.2 Materials and methods 
2.2.1 Participants 
The participants were healthy men (n = 40) aged 21-50 y with a body mass index 
(BMI) of 20-29.9 kg/m2, whom were recruited from Cornell University and the Ithaca 
area from May-July 2014 as previously described [13]. Women, vegetarians, and 
smokers were excluded from the study, as were men with a BMI ≥ 30 kg/m2, age over 
50 y, or had values outside of normal range for indices of organ function (based on 
their blood chemistry profile). Men who indicated in a health history questionnaire 
having gastrointestinal diseases or complaints, chronic illnesses or other metabolic 
diseases, or taking nutritional supplements, antibiotics or probiotics within 2 months 
of recruitment were also excluded. The study was approved by the Institutional 
Review Board for Human Study Participants at Cornell University (Protocol ID#: 
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1403004534), and all participants signed a written informed consent prior to study 
enrollment.  
2.2.2 Study design and protocol 
The study is a single-arm feeding trial embedded within a randomized trial. The 
original study was a four-arm crossover feeding study with one-week washout periods 
in which study participants consumed one of the following meals in random order: 
eggs, beef, fish and fruit-control [13]. At the fruit-control study meal, a TMAO tracer 
was administered to enable investigation of its metabolic fate, which is the focus of the 
current study. 
A day prior to the fruit-control study session, participants were advised to avoid 
consumption of foods that can decrease FMO enzyme activity and alter TMAO 
metabolism (i.e., grapefruit juice and indole-containing vegetables including broccoli, 
Brussels sprout, cabbage, cauliflower, kale, and bok choy) [15]. The participants were 
also asked to maintain their normal dietary and lifestyle routine, including their 
exercise routine the day prior to the study session.   
The deuterium-labeled methyl-d9-TMAO (d9-TMAO) stock solution was prepared 
by dissolving 1 g d9-TMAO powder (Cambridge Isotopes, Tewksbury, MA) in 10 mL 
drinking water, dispensing 500 μL (50 mg) of it into 50-mL conical tubes, and storing 
at -80°C. Immediately before consumption, the 50-mg d9-TMAO concentrate was 
thawed and mixed with drinking water to yield the final volume of 1 cup (237 mL). A 
dose of 50 mg d9-TMAO was provided because i) it achieves enrichment levels in 
blood and urine that are readily measured by liquid chromatography-tandem mass 
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spectrometry (LC-MS/MS), ii) it is a physiologically relevant amount, and iii) it is 
well within the range of deuterium that can be administered safely [16].  
On the session day, participants arrived at the Human Research Metabolic Unit 
(HMRU) at Cornell University between 07.00 and 10.00 in the fasted state (10 h). 
Participants completed a 24-h dietary recall to ensure compliance to the food 
restriction and were queried about deviations from their usual dietary and lifestyle 
routine. Participants who did not comply with the food restriction or who deviated 
from their usual dietary and lifestyle routine were rescheduled. Participants then 
consumed 1 cup (237 mL) of water containing 50 mg d9-TMAO along with 2 single-
serve packages of applesauce (Mott’s natural applesauce; Tops), the non-TMAO 
containing control food of the parent study [13]. Following the consumption of the d9-
TMAO tracer, serial blood samples were collected at 15, 30 min, 1, 2, 4 and 6 h, and 
urine voids produced during this 6-h study period were pooled. At 4.5 h, participants 
were provided a fruit snack (2 single-serve packages of applesauce) to ease hunger 
without interfering with the study protocol. The participants remained at the testing 
site throughout the study period, and they were not allowed food or beverages (except 
water) outside of those provided by study personnel. Following the testing session, the 
participants turned in self-collected 6-24-h post study urine and a stool sample 
(collected in whole from the first bowel movement). 
2.2.3 Sample collection and processing 
At screening, fasting serum and buffy coat were collected for blood chemistry 
profiling [17] and FMO3 G472A (rs 2266782) genotyping. During the study period, 
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whole blood was collected in EDTA-coated tubes (Becton, Dickinson and Company) 
and processed on-site for plasma metabolite measurements as previously described 
[18]. Urine was collected in wide-mouth polyethylene bottles (1 L; Nalgene) during 
the 6-h study period and the 6-24 h post-study, and the volumes were recorded 
separately. Additionally, participants collected a complete bowel movement in a 
provided bag, kept the stool frozen, and delivered it in insulated thermal bags. Thawed 
stool weight was recorded. All samples were de-identified, distributed and stored at -
80 °C. Personnel involved in sample collection and processing were blinded to 
participant identities. 
2.2.4 Muscle biopsy 
A subset of participants (n = 6) volunteered to undergo skeletal muscle biopsy 6 h 
after the fruit + d9-TMAO tracer consumption so that tissue uptake could be 
examined. The inclusion criteria for muscle biopsy were participants with no history 
of a negative or allergic reaction to local anesthetics, with no tendency toward easy 
bleeding or bruising, not currently on any medications that may increase the chance of 
bleeding or bruising (e.g., Aspirin, Coumadin, Anti-inflammatories, Plavix), not 
currently on any immunosuppressive medications (e.g., glucocorticoid steroids, 
chemotherapy), with no current disease processes that would impair the healing 
process (e.g., diabetes, cancer, keloids, hereditary healing disorders, jaundice, 
alcoholism, HIV/AIDS), and with no history of fainting when undergoing or watching 
medical procedures. All participants signed a written informed consent prior to the 
procedure. 
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The skeletal muscle biopsy was performed at Gannett Health Services at Cornell 
University by a trained nurse practitioner. Using aseptic techniques, local anesthetic 
(Lidocaine hydrogen chloride 1%) was applied to numb the area of the muscle above 
the knee. A small 1 cm incision was made using a scalpel through the skin, and the 5 
mm Bergstrom muscle biopsy needle was inserted into the muscle belly. Suction was 
applied using a syringe to obtain a small sample of muscle tissue (~200 mg) which 
was then distributed into cryogenic tubes (Fisher Scientific), rapidly frozen in liquid 
nitrogen, and stored at -80 °C. Immediately following the biopsy, pressure was 
applied, and thin adhesive strips and pressure dressing were used to close the wound. 
2.2.5 Metabolite measurements 
TMAO and its derivatives TMA, DMA and MA were extracted from plasma, 
muscle, urine, and stool samples as previously described [13]. Unlabeled metabolite 
concentrations in plasma and muscle were measured by isotope-dilution LC-MS/MS 
protocol [13] using Surveyor HPLC system TSQ Quantum Ultra mass spectrometer 
(ThermoElectron Corp), while those in urine and stool were measured using an Accela 
HPLC system TSQ Quantum Access mass spectrometer (ThermoElectron Corp). At 
that time, a separate run without internal standards was used to determine the relative 
intensities of unlabeled and labeled metabolites.  The following precursor → product 
ion pairs were used for detection of these metabolites: m/z 76.3 → 58.4 for TMAO, 
m/z 79.3 → 61.4 for d3-TMAO, m/z 82.3 → 64.4 for d6-TMAO, and m/z 85.3 → 66.4 
for d9-TMAO. TMA, DMA and MA derivatized with EBA had transitions as follow: 
m/z 146.1 → 118.1 for TMA-EBA, m/z 149.1 → 121.1 for d3-TMA-EBA, m/z 152.1 
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→ 124.1 for d6-TMA-EBA, m/z 155.1 → 127.1 for d9-TMA-EBA, m/z 132.1 → 58.1 
for DMA-EBA, m/z 135.1→ 107.1 for d3-DMA-EBA, m/z 138.1 → 64.2 for d6-
DMA-EBA, m/z 118.1 → 44.3 for MA-EBA, and m/z 121.1 → 47.3 for d3-MA-EBA. 
Peak area under the chromatography curve of the labeled and unlabeled metabolites 
was acquired and analyzed using the XCalibur program (ThermoElectron Corp).  
2.2.6 Calculation of metabolite enrichments, concentrations, and 
pharmacokinetics 
Isotopic enrichment percentages were calculated by dividing the peak area under 
the chromatography curve of the labeled metabolite by the total area of the labeled 
plus unlabeled metabolites. These enrichments were used to monitor the flow of orally 
consumed TMAO (d9-TMAO) through the TMAO pathway. Because isotopic 
enrichments account for inter-person variation in metabolite pool size, they provide a 
less biased indication of the flow than absolute concentrations. Metabolite enrichment 
ratios were also examined as indicators of the flow of the tracer through specific steps 
of the TMAO pathway.  
In addition, the partitioning of the tracer among body compartments shown in Table 
2.1 was determined by calculating the concentrations of labeled metabolites, which 
were derived from the concentrations of the unlabeled metabolites measured in the 
parent trial [13] using similar protocols and the same instrumentation. This derivation 
was comprised of two steps. The first step was to determine the concentrations of the 
labeled metabolite by using the following equation: peak area of labeled 
metabolite/peak area of unlabeled metabolite × unlabeled metabolite concentration. 
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The second step involved estimating the total amount of labeled metabolites in each 
body compartment (i.e., plasma, muscle, urine and stool), which equaled the average 
labeled metabolite concentration × the average size of a body compartment. The latter 
was specified as follows: plasma, 41.25 mL/kg body weight (assuming plasma is 55% 
v/v of blood and average blood volume is 75 mL/kg body weight); muscle, 33.7 kg 
based on our participants’ average body weight and age [20]; urine, recorded volumes; 
stool, recorded weights. 
As an exploratory analysis, turnover rate (h-1), the rate at which the whole pool of 
a metabolite is renewed, was calculated by dividing the pool size of total TMAO 
enrichment (d9 + unlabeled TMAO = 100%) by the formation rate of plasma d9-
TMAO (% per h). The latter was estimated from the slope of d9-TMAO enrichments 
from 30 min to 2 h (Figure 2.1A), with the assumption that equilibrium of TMAO was 
established at 1 h based on the d9-TMAO response curve shown in Figure 2.1A. 
Turnover time was the reciprocal of the turnover rate. 
2.2.7 Genotyping 
DNA was extracted from monocytes collected at screening according to the 
manufacturer’s protocol (Dneasy Tissue kit, Qiagen Science). The most common 
variant flavin-containing monooxygenase isoform 3 (FMO3) G472A (rs2266782; 
E158K) reported to influence N-oxygenation of TMA [19] was determined for each 
participant by endpoint genotyping using a fluorescent Taqman SNP genotyping assay 
kit (Thermo Scientific, catalog no. 4362691) on the LightCycler® 480 real-time PCR 
instrument (Roche). The genotyping was performed according to the manufacturer’s 
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protocol with cycling conditions of 10 min hold at 95C, followed by 34 cycles of 
92C for 15 s and 62C for 90 s. Samples were run in duplicate with in-run standards 
and a negative water control. 
2.2.8 Quantitative real-time RT-PCR 
RNA was extracted from frozen muscle biopsy samples (~30mg) using TRIzol 
reagent (Invitrogen) and the RNeasy Mini Kit (Qiagen). RNA concentration and 
quality were assessed with a NanoDrop ND-1000 spectrophotometer (Thermo). All 
samples had A260/A280 ratios above 1.8. One sample showed contamination and thus 
was excluded from subsequent procedures. Reverse transcription was performed on all 
five samples using the ImProm-II Reverse Transcription System (Promega). 
Quantitative PCR was performed using LightCycler 480 SYBR Green I Master 
(Roche) in a LightCycler 480 instrument (Roche). Primers were designed using NCBI 
Primer-BLAST. Sequences were as follows: FMO3, 
F/5' GAAGAAAGTGGCCATCATTGGAG 3', R/ 5' AATTTCCACAGGCCCCCAA 
3'; GAPDH, F/ 5' TGTTGCCATCAATGACCCCTT 3', R/ 5' 
CTCCACGACGTACTCAGCG 3'. Reaction conditions were as follows: 95°C for 5 
minutes, followed by 40 cycles with 15 sec at 95°C, 30 sec at 60°C, and 30 sec at 
72°C. All samples were run in triplicate. A melting curve analysis was included at the 
end of the amplification cycles to verify successful amplification of the PCR product 
and specificity was confirmed by running products on agarose gels. Expression levels 
of FMO3 were calculated by the ΔCt method normalized to the expression of 
reference gene GAPDH (glyceraldehyde 3-phosphate dehydrogenase). 
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2.2.9 Statistical analyses 
Metabolite enrichments were analyzed descriptively by calculating averages and 
standard deviations at each time point for plasma, muscle, urine and stool. 
Furthermore, a repeated measures mixed linear model was employed to investigate 
enrichment percentage as a function of time and/or genotype for individual 
compartments. Tukey-Kramer post-hoc test was used to correct for multiple 
comparison among the time points and the genotypes. The residuals were inspected for 
violation of model assumptions, and the data was logarithmically transformed if 
needed. Significant differences are reported at P < 0.05. All model-based results are 
expressed as means ± SEM. All statistical analyses were conducted using SAS 
(version 9.4, SAS Institute, NC) with the PROC MIXED model procedure with 
random slopes and intercepts, and unstructured covariance structure.  
2.3 Results 
2.3.1 Labeled TMAO metabolites in the circulation 
After oral consumption of the tracer, d9-TMAO was detected in plasma as early as 
15 min, then increased rapidly during the first hour and remained elevated at 66– 
75% enrichment throughout the 6-h study period (Figure 2.1A). Based on this  
observation, further exploratory analyses were conducted to derive an estimated 
turnover rate and turnover time of 0.19 h-1 and 5.3 h, respectively for TMAO (see 
methods section for calculations).  Compared to d9-TMAO, d9-TMA and d6-DMA 
appeared in plasma more gradually. Plasma d9-TMA continuously increased at most  
time points, achieving 52% enrichment at 6-h, while plasma d6-DMA was not 
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detected until after 2-h, when it increased significantly and rather exponentially, 
achieving 3% enrichment at 6-h (Figure 2.1). Notably, enrichments all of the labeled 
TMAO metabolites in the circulation varied greatly among participants, ranging from 
26 to 92% for TMAO, 12 to 82% for TMA, and 0 to 10% for DMA at 6 h. 
To examine TMAO pool size in relation to the inflow of the tracer, total TMAO 
concentration (labeled + unlabeled) was calculated and compared with d9-TMAO 
enrichment (Figure 2.2). Although the former exhibited a slight logarithmic increase, 
the latter, which reflects the flux of labeled TMAO, increased more rapidly as 
indicated by the steeper slope. Unlabeled (i.e., endogenous) TMAO concentrations 
remained constant throughout this time period (Supplementary Figure 2.1).  
2.3.2 Skeletal muscle uptake of labeled TMAO metabolites and modulation by 
FMO3 G472A 
At 6 h after tracer consumption, d9-TMAO comprised 36% enrichment in skeletal 
muscle, while d9-TMA comprised 3.3% enrichment. Moreover, d9-TMAO and d9-
TMA in muscle correlated rather strongly with those in plasma, but statistical 
significance was not achieved (d9-TMAO Pearson’s r = 0.65, P = 0.16; d9-TMA 
Pearson’s r = 0.70, P = 0.12). Neither d9-TMAO nor d9-TMA was associated with 
FMO3 G472A polymorphism in our sample of three heterozygous GA and three 
homozygous wild-type GG genotypes. However, the GA genotype had a lower muscle 
d9-TMAO:d9-TMA (product: precursor) ratio than the GG genotype (P = 0.047) 
(Supplementary Figure 2.2) despite a very low mRNA expression level (0.000464 fold 
over GAPDH expression) of FMO3 in muscle. Paradoxically, no effect of the FMO3 
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Figure 2.1 A) Plasma d9-TMAO (circle), d9-TMA (triangle) and B) d6-DMA enrichments 
increased within 6 h after consumption of the 50 mg d9-TMAO tracer. Isotopic 
enrichment percentage was calculated by dividing the peak area under the 
chromatography curve of the labeled metabolite by the sum of the peak area of 
the labeled plus unlabeled metabolites. For each metabolite, significant 
differences (P < 0.05) among the timepoints were determined using repeated 
measure mixed linear model and the Tukey-Kramer post-hoc test for multiple 
comparison correction, and are denoted by different letters. Values are mean ± 
SD; n = 40 per time point per metabolite. Abbreviation: d6-DMA = Deuterium-
labeled methyl d6-dimethylamine; d9-TMA = d9-trimethylamine; d9-TMAO = 
d9-trimethylamine-N-oxide 
G472A polymorphism was detected in other compartments when all participants were 
included in the analysis, as opposed to just those who had undergone a muscle biopsy. 
Other labeled metabolites (i.e., d6-DMA and d3-MA) were not detected in muscle.  
2.3.3 Excretion of labeled TMAO metabolites 
d9-TMAO enrichment in urine was higher during 0-6 h (67%) than 6-24 h (52%) 
after consumption of the tracer (Figure 2.3). d9-TMA enrichment did not differ during  
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Figure 2.2  Following oral administration of the 50 mg deuterium-labeled methyl d9-
trimethylamine-N-oxide (d9-TMAO) tracer, plasma d9-TMAO enrichment 
(triangle) increased more rapidly than total TMAO concentration (circle) [d9 + 
unlabeled TMAO]. d9-TMAO enrichment percentage was calculated by dividing 
the peak area under the chromatography curve of the labeled metabolite by the 
sum of the peak area of the labeled plus unlabeled metabolites. d9-TMAO 
concentration was derived from data published separately [13] by using the peak 
area of d9-TMAO / peak area of unlabeled TMAO × unlabeled TMAO 
concentration. The units of the y-axis are shown below the plotting area. Dashed 
lines are best-fitted logarithmic trend lines with indicated equations and R2-
values. Values are mean ± SD, n = 40 per time point. 
these periods (~48%). Urinary d6-DMA enrichment was lower during the 0-6 h (1%) 
than the 6-24 h (4%) periods. In addition, compared to urine, d9-TMA enrichment in 
stool was lower (4% vs. 46%), while d6-DMA was higher (15% vs. 4%). d9-TMAO 
and other labeled metabolites were not detected in stool. 
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Figure 2.3:  The 50 mg d9-TMAO tracer was excreted as d9-TMAO, d9-TMA and d6-DMA 
in urine 0-24 h after oral administration. d9-TMAO enrichments were higher 
during 0-6 h (black) than 6-24 h (white), while d9-TMA enrichments did not 
differ between the two periods. d6-DMA enrichments were higher during 6-24 h. 
Isotopic enrichment percentage was calculated by dividing the peak area under 
the chromatography curve of the labeled metabolite by the sum of the peak area 
of the labeled plus unlabeled metabolites. Significant differences (P < 0.05) 
between the two periods are determined using repeated measure mixed linear 
model for each metabolite. Values are mean ± SEM; n = 40 per time period per 
metabolite. Abbreviation: d6-DMA = Deuterium-labeled methyl d6-
dimethylamine; d9-TMA = d9-trimethylamine; d9-TMAO = d9-trimethylamine-
N-oxide 
2.3.4 Estimated distribution of labeled TMAO metabolites 
Table 2.1 shows estimates of d9-TMAO and methylamine derivatives as 
percentages of the tracer dose for each body compartment. At 6-h, an estimated 5.6% 
of the dose was present in plasma, 19% in skeletal muscle, and 42% in urine, mostly 
as d9-TMAO. An estimated 0.15% of the dose was detected in stool mainly as d9-  
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Table 2.1: The distribution of the 50 mg d9-TMAO oral dose within body compartments 
 
 
 
 
 
 
 
 
 
1 Percentage of dose was estimated from the concentrations of labeled metabolites, which 
were derived from the concentrations of the unlabeled metabolites measured in the parent 
trial [13] using the following equation: peak area of labeled metabolite/peak area of 
unlabeled metabolite × unlabeled metabolite concentration. Next, the total amount of labeled 
metabolites in each body compartment were estimated using the average labeled metabolite 
concentration × the average size of a body compartment. The latter was specified as follows: 
plasma, 41.25 mL/kg body weight (assuming plasma is 55% v/v of blood and average blood 
volume is 75 mL/kg body weight); muscle, 33.7 kg based on our participants’ average body 
weight and age [20]; urine, recorded volumes; stool, recorded weights. Finally, the total 
amount of labeled metabolites was converted to percentage of the 50-mg d9-TMAO dose. 
Total methylamines equal the sum of d9-TMAO, d9-TMA and d6-DMA. Abbreviation: d6-
DMA = Deuterium-labeled methyl d6-dimethylamine; d9-TMA = d9-trimethylamine; d9-
TMAO = d9-trimethylamine-N-oxide  
2 n = 40 per compartment per metabolite  
TMA. After 24-h, an estimated 96% of the administered dose was excreted in urine 
mainly as d9-TMAO, leaving 4% (2 mg) retained in the body. 
 % of d9-TMAO oral dose1 ± SEM 
 d9-TMAO d9-TMA d6-DMA Total2 
Plasma at 6 h3 5.5 ± 0.3 0.01 ± 0.001 0.03 ± 0.004 5.6 
Muscle at 6 h3 19 ± 5.6 0.14 ± 0.03 - 19 
Urine     
0-6 h3 42 ± 2.7 0.08 ± 0.02 0.18 ± 0.04 42 
6-24 h3 52 ± 3.9 0.16 ± 0.03 1.5 ± 0.16 53 
Total (0-24 h) 94 ± 5.1 0.24 ± 0.05 1.7 ± 0.18 96 
Stool after 6 h4 - 0.13 ± 0.05 0.02 ± 0.01 0.15 
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2.4 Discussion 
This study traced the metabolic fate of orally consumed TMAO in humans using a 
stable isotope approach. Our findings demonstrate that orally consumed TMAO i) is 
largely absorbed and does not require processing; ii) has a high turnover and rapid 
clearance and iii) is taken up by extrahepatic tissue. The proposed fate of labeled 
TMAO based on the study findings is illustrated in Figure 2.4.  
2.4.1 Absorption of orally consumed TMAO is near complete and does not 
require processing by the gut microbes and hepatic FMOs 
The orally consumed d9-TMAO tracer was rapidly absorbed, achieving ~20% 
enrichment in the systemic circulation within 15-min of consumption (Figure 2.1A).  
This timing of events suggests that a portion of orally consumed TMAO can be 
absorbed from the intestine independent of its conversion to TMA by gut microbiota 
and subsequent reversion to TMAO by hepatic FMOs. Furthermore, d9-TMAO 
occupied more than half of the endogenous pool slightly after 30 min, at which time 
d9-TMA was barely detected in plasma, thereby providing additional support that the 
majority of orally consumed TMAO is absorbed intact. 
Although the majority of TMAO appeared to be absorbed intact, detection of d9-
TMA and d6-DMA in plasma, urine and stool suggests that microbial and/or hepatic 
processing also occurs to a limited extent. These metabolites may be formed when d9-
TMAO passes through the gastrointestinal tract or when absorbed d9-TMAO is 
secreted to the intestine. Nonetheless, d6-DMA was not detected in plasma until two 
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Figure 2.4: A simplified schema of the metabolic fate of orally consumed TMAO and its 
methylamine derivatives. The majority of d9-TMAO is absorbed intact into the 
systemic circulation. A portion of the tracer undergoes microbial conversion to 
form d9-TMA and d6-DMA. Minor portions of these metabolites are lost in feces, 
but the majority is absorbed into the liver, where hepatic enzyme FMO3 converts 
d9-TMA mainly to d9-TMAO. These metabolites subsequently enter the systemic 
circulation. Circulating TMAO exhibits fast turnover with the majority being 
eliminated in urine. However, a small portion of the dose, potentially the portion 
generated by hepatic FMO3, is taken up by extrahepatic tissue. The direction of 
the arrows indicates the flow of the labeled metabolites through the body. The size 
of the arrows indicates relative magnitude of the flow. Abbreviation: d6-DMA = 
Deuterium-labeled methyl d6-dimethylamine; d9-TMA = d9-trimethylamine; d9-
TMAO = d9-trimethylamine-N-oxide; FMO3 = Flavin-containing 
monooxygenase isoform 3 
hours post consumption (Figure 2.1B) suggesting that conversion of TMA to DMA 
(and/or absorption of DMA) is slow within the gut, or that this conversion mostly 
transpires in the liver. Importantly, the absorption of d9-TMAO, d9-TMA and d6-
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DMA was near complete (~96% of the dose) with no d9-TMAO detected in feces 
(Table 2.1). It is also worth noting that although TMAO molecules bear structural 
similarity to choline, we found no evidence for the use of TMAO’s methyl groups in 
one-carbon metabolism (e.g., d3-methionine was not detected in any compartments 
investigated).  
2.4.2 TMAO exhibits a high turnover rate and rapid clearance 
Incorporation of the label into the TMAO pool occurred rapidly such that d9-
TMAO comprised 66% enrichment within the first hour and reached 76% 6 h after 
tracer consumption (Figure 2.1A). These enrichments are indicative of a high turnover 
rate such that new TMAO molecules are largely replacing the endogenous TMAO 
pool. Although the total pool size of TMAO (d9 + d0 TMAO) also expanded (Figure 
2.2), plasma d9-TMAO enrichments, which indicate the influx of d9-TMAO 
molecules, increased at a much greater rate than the pool size. Indeed the increase in 
pool size was due to the rapid increase in d9-TMAO enrichment, given the lack of 
change in unlabeled TMAO concentrations during this period (Supplementary Figure 
2.1). Given that the initial increase (15 min-1 h) of d9-TMAO enrichment was 
approximately linear, and the new equilibrium was established at 1 h, we were able to 
calculate the formation rate of plasma TMAO and the steady-state pool size. From 
these data, we identified a plasma TMAO turnover rate of 0.19 h-1 and a turnover time 
of 5.3 h. This is slower compared to TMAO turnover rates in rat models [21] possibly 
because of the larger pool size in humans. Nonetheless, compared to those of many 
common medicinal agents, TMAO turnover rate is relatively fast [22,23]. 
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In addition to a high turnover rate in plasma, orally consumed TMAO is also 
rapidly and efficiently cleared in urine within 24 h of consumption. d9-TMAO 
comprised 52-67% enrichment within 24-h of tracer consumption (Figure 2.3), 
indicating rapid elimination of TMAO. In addition, urinary d9-TMAO enrichment was 
highest during 0-6 h after consumption, suggesting that elimination is greatest during 
this period.  On the other hand, TMA and DMA excretion appear to be slower than 
that of TMAO as indicated by their lower urinary enrichments. Slower excretion of 
TMA and DMA is consistent with the order of their metabolic production (Figure 2.4). 
This sequential production and excretion were also observed in changes in urinary 
enrichments over time (Figure 2.3). Specifically, d9-TMA was excreted constantly, 
while d6-DMA had prolonged excretion with greater elimination rates in the 6-24 h 
period as compared to the 0-6 h period. Notably, approximately 96% of the dose was 
detected mainly as d9-TMAO within 24 h (Table 2.1), indicating that orally consumed 
TMAO is efficiently cleared in urine.  
2.4.3 TMAO is taken up by extrahepatic tissue  
d9-TMAO and d9-TMA were detected in skeletal muscle within 6 h of 
administering the tracer, indicating for the first time that these metabolites can be 
taken up by extrahepatic tissue in humans. Interestingly, in our cohort, the FMO3 
G472A genotype was associated with the skeletal muscle ratio of TMAO:TMA (and 
TMA:TMAO) (Supplementary Figure 2.2). Specifically, a lower d9-TMAO:d9-TMA 
enrichment ratio was detected among men with the heterozygous GA genotype as 
compared to those with the wild-type GG genotype. Given the very low level of 
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FMO3 transcript abundance in the skeletal muscle of our participants, which is 
consistent with an absence of skeletal muscle FMO3 protein as reported by others 
[24], our findings suggest that the effect modification of the d9-TMAO:d9-TMA ratio 
by genotype in muscle reflects the hepatic activities of FMO3 in the GG and GA 
genotypes. As such, these data imply that the plasma TMAO pool is comprised of at 
least two kinetic pools that differ in their metabolic fates: one that bypasses the liver 
and is largely excreted and one that is generated from hepatic FMO3 and imported 
into tissues.  
2.4.4 Study limitations  
Our study illustrates the metabolic fate of TMAO and uncovers potentially novel 
aspects of TMAO metabolism. However, the current study design did not permit 
calculation of absolute bioavailability, which is the fraction of the oral dose that 
reaches the systemic circulation relative to an intravenous dose. In addition, the 
turnover parameters, which are often calculated using an elimination curve, were 
estimated based on the formation curve, and the results presented in Table 2.1 are 
crude estimates calculated using linear curves for unlabeled metabolites. We also had 
limited power to detect the genetic effect of variants in FMO genes on TMAO 
metabolism. Finally, the reported kinetics of TMAO solutions may differ from that of 
TMAO in food matrices. 
2.4.5 Conclusion and clinical implications 
Absorption of orally consumed TMAO is near complete, and may occur largely by 
a process that is independent of gut microbes and hepatic FMOs. In healthy men, 
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TMAO exhibits fast turnover in the circulation with the majority being eliminated in 
urine. A small portion of the dose, however, is taken up by extrahepatic tissue in a 
manner that appears to be under the influence of FMO3 G472A polymorphism.  From 
a clinical perspective, our findings show that circulating TMAO concentrations in a 
healthy population are temporarily elevated as a result of intake of the intact TMAO 
molecules, which are abundant in fish and seafood. This elevation does not necessarily 
depend on gut microbiota as observed upon consumption of dietary precursors of 
TMAO like choline. Moreover, TMAO is rapidly eliminated in healthy adults which is 
in contrast to the sustained elevation of TMAO in atherosclerotic patients [3,4,6] and 
elevated TMAO concentrations due to gut microbial processing of TMAO precursors 
in disease animal models [4,6]. Finally, the discovery of TMAO uptake by 
extrahepatic tissue may signify a physiological role of this metabolite in humans.  
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ABSTRACT 
Dietary choline is a precursor of trimethylamine N-oxide (TMAO), a metabolite 
that has been associated with an increased risk of cardiovascular disease. The 
mechanism underlying this association is unknown, but may include TMAO effects on 
blood pressure. This study assessed the association of choline intake with hypertension 
and blood pressure (BP) using cross-sectional data from the 2007 to 2010 National 
Health and Nutrition Examination Survey (NHANES). Modifying factors (sex, 
race/ethnicity) and dietary versus supplemental sources of choline intake were also 
investigated. The associations of total (dietary + supplemental) and dietary choline 
intake with the prevalence odds of hypertension differed by sex (n=9,227; 
Pinteraction=0.04). In women, both total and dietary choline intake had a borderline 
inverse association with hypertension (n=4,748; prevalence odds ratio [OR] per 100 
mg of total choline and 95% confidence interval [95% CI] was 0.89 [0.77 – 1.02], P < 
0.10), but no association was observed in men (n=4,479; P=0.54). Use of choline 
supplements was inversely associated with hypertension in both sexes (prevalence OR 
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[95% CI], 0.68 [0.49 – 0.92]; P=0.01). There was little to no association of total, 
dietary, or supplemental choline intake with systolic or diastolic BP (n=6,554; mmHg 
change in BP associated with 100 mg difference in total choline ± SEM was -
0.26±0.22 mmHg and -0.29±0.19 mmHg, respectively). In summary, the cross-
sectional NHANES data do not support the hypothesis of a positive association 
between choline intake and BP. 
3.1 Introduction 
Hypertension affects 85.7 million Americans or 34% of the population [1] and is a 
major risk factor for atherosclerosis and cardiovascular disease (CVD).  Genetic 
predisposition combined with exposure to environmental factors such as unhealthy 
diets and lifestyles can lead to abnormal regulation of blood pressure and development 
of hypertension. Elevated blood pressure stimulates collagen production, which 
contributes to intima-media thickening, vascular stiffening, and endothelial 
dysfunction with increasing age [2]. This vascular wall remodeling promotes 
expression of pro-inflammatory cytokines, growth factors, adhesion molecules, as well 
as infiltration of macrophages and vascular smooth muscle cells [2]; all of which are 
predominant pathophysiologic features in the development of atherosclerosis.  
Choline, a nutrient found mostly in animal source foods, was recently shown to 
predict CVD risk in humans and to promote atherosclerosis in mice through its gut-
dependent metabolism to trimethylamine-N-oxide (TMAO) [3]. Upon consumption, 
unabsorbed choline is metabolized by gut microbiota to trimethylamine and 
subsequently, by hepatic enzyme flavin-containing monooxygenases (FMOs), to 
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TMAO [3,4]. Epidemiologic evidence links elevated TMAO concentrations to adverse 
cardiovascular events [5], but whether CVD is associated with dietary intake of 
choline is unclear [6]. Mechanistic studies in apolipoprotein E knockout mice 
supplemented with choline and/or TMAO reported enhanced macrophage foam cell 
formation [3] and reduced reverse cholesterol transport [7], although in mice 
expressing human cholesteryl ester transfer protein, TMAO was inversely correlated 
with aortic lesion size [8], TMAO was also shown to prolong the hypertensive effects 
of angiotensin II in rats [9] suggesting a possible effect of the choline-derived 
metabolite on blood pressure. 
In this study, we investigated the association of choline intake with both blood 
pressure and the prevalence odds of hypertension, using data from the 2007 to 2010 
cross-sectional National Health and Nutrition Examination Survey (NHANES) 
[10,11]. 
3.2 Methods 
3.2.1 Study population 
The study population was drawn from the cross-sectional, publicly-accessible 
NHANES survey data from 2007 to 2010 (n = 20,686) [10,11]. The programming 
code that produced the findings described herein is available by request. NHANES 
used a complex, multistage probability sampling design to obtain a representative 
sample of the civilian, noninstitutionalized U.S. population [12]. National Center for 
Health Statistics Research Ethics Review Board approved all NHANES protocols, and 
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all participants gave informed consent [12]. The current study included non-pregnant 
individuals aged ≥ 20 y who completed two 24-h recalls with non-extreme caloric 
intakes (n = 9,559; Supplementary Figure 3.1). The sample was further refined using a 
priori criteria to yield the final analytic samples for the evaluation of the hypertension 
and blood pressure outcomes. For the hypertension outcome, individuals were 
considered to be hypertensive (n = 3,933) or non-hypertensive (n = 5,626) based on 
the definitions of hypertension described below.  Non-hypertensive individuals with 
incomplete data on the variables used to define the presence/absence of hypertension 
were omitted from further consideration (n = 332), yielding 9,227 participants in the 
analysis of choline—hypertension. For the analysis of the choline—blood pressure 
association, participants with missing or non-positive blood pressure (n = 314) or who 
reported using anti-hypertensive medications (n = 2,691) were omitted from further 
consideration (n = 6,554 for analysis). 
3.2.2 Choline intake measurement  
Two 24-h dietary recalls were collected using the validated Automated Multiple 
Pass Method by trained interviewers [13,14]. Immediately after the dietary recalls, 24-
h dietary supplement usage was collected using a similar protocol. The first dietary 
recall was conducted in person at the mobile examination centers, while the second 
occurred via follow-up phone calls. Total amounts of dietary choline were determined 
using nutrient values from the Food and Nutrient Database for Dietary Studies [13], 
and amounts of supplemental choline were calculated from a database of label 
information. The sum of dietary and supplemental choline yielded total choline intake 
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for each recall day. The average total and dietary choline intake across the two recall 
days were used as continuous variables in all analyses.  
Use of dietary supplements during the past 30 days was collected at the 
participants’ homes using a questionnaire administered by trained interviewers. 
Amounts of supplemental choline were calculated from supplement labels. 
Supplemental choline variables in both the 24-h recalls and the 30-day questionnaire 
were modeled as binary variables (user vs. non-user). 
3.2.3 Covariates   
The covariates considered as possible confounding variables were sex, age, 
race/ethnicity (non-Hispanic White; non-Hispanic Black; Hispanic, Mexican 
American, and others), ratio of family income to poverty level, education (< 9th grade, 
9-11th grade, high school graduate, some college, college graduate), marital status 
(yes, no), physical activity (h/wk of moderate-vigorous activities), smoking (never, 
former, current), menopausal status and hormone replacement therapy usage; all 
variables were self-reported (Supplementary Table 3.1). Weight and height were 
measured using standardized methods [15] and used to calculate body mass index 
(BMI, kg/m2). Total calories, protein and fat, cholesterol, sodium, folate, vitamin B6 
and vitamin B12 intakes from foods and supplements were obtained from the average 
of two 24-h recalls, with calculations as described above for choline.  
Covariates that were associated with choline intake, causally associated with blood 
pressure or hypertension, and that had a demonstrable influence on the effect estimates 
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were retained in the models. Final model covariates were: age, sex, race/ethnicity, 
BMI, total calories, education and poverty ratio. 
3.2.4 Outcomes   
The primary outcomes were hypertension prevalence and systolic and diastolic 
blood pressure (SBP and DBP, respectively). Hypertension status was assessed using 
data collected during the interview and examination. The protocol for blood pressure 
measurement is reported elsewhere [15]. Hypertensive individuals were defined by the 
following criteria: 1) reported having been told by doctors 2+ times of hypertension 
diagnosis, or 2) reported using antihypertensive medication(s), or 3) had mean SBP ≥ 
140 mmHg and/or DBP ≥ 90 mmHg (calculated from 1-3 readings at one sitting). 
Non-hypertensive individuals were defined as participants without any evidence of 
hypertension, i.e., not meeting the above criteria. In addition to models estimating the 
association of choline with prevalent hypertension, separate statistical models 
estimated the association of choline with SBP and DBP.   
3.2.5 Statistical analysis   
Sample weights were used according to the NHANES analytic guidelines to 
account for complex survey design in all analyses [16]. Population means, 
proportions, and standard deviations of baseline characteristics in Supplementary 
Table 3.1 were estimated [17]. Population means of dietary variables were adjusted for 
total calories using the residual method [18] and standardized to 2,000 kcal. 
Associations between choline intake and the prevalence odds of hypertension and 
blood pressure were assessed using logistic regression and multiple linear regression, 
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respectively. All analyses were adjusted for the above-mentioned covariates unless 
otherwise noted; about 10% of participants were missing on covariates in each 
analysis (n = 878 missing in hypertension models; n = 615 missing in blood pressure 
models). Estimated regression coefficients for choline were based on participants with 
complete data on all covariates, while the variances of the estimates were adjusted for 
missing values in the covariates (NOMCAR option).  In addition, sex, race/ethnicity, 
BMI, post-menopausal status and use of hormone replacement therapy were tested as 
effect modifiers of the choline—hypertension/blood pressure associations. Further 
analyses considered the associations of dietary intake or supplemental intake of 
choline in separate models. Sensitivity analyses considered similarity of associations 
when supplemental choline intake data were obtained from 24-h recalls versus the 30-
day questionnaire. 
The primary analyses and statistically significant results were followed by three 
planned sensitivity analyses. First, participants with <3 blood pressure readings were 
excluded. Second, participants with CVD endpoints defined as self-reported 
congestive heart failure, coronary heart disease, angina, heart attack or stroke were 
excluded. Finally, hypertension status was categorized into “definite” (2 or all 3 
classification features), “probable” (1 or 2 classification features) or “possible” (1 
classification feature) based on each participant’s available data (Supplemental 
Methods). All analyses were conducted using SAS (version 9.4, SAS Institute, NC) 
with a significant threshold of two-sided P < 0.05 and a trended association at P < 0.1. 
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3.3 Results 
3.3.1 Associations between choline intake and hypertension 
The prevalence of hypertension during 2007-10 in the analytic sample was 43%.  
Hypertensive participants had 12 mg higher energy-adjusted choline intake, a lower 
proportion of supplemental choline users, and higher SBP and DBP, compared to non-
hypertensive participants (Supplementary Table 3.1). Additionally, compared to the 
non-hypertensive group, the hypertensive group was more likely to be non-Hispanic 
White or non-Hispanic Black, older, married, post-menopausal, former smoker, high 
school or lower education level, higher BMI, and lower on physical activity. 
Compared to non-hypertensives, the hypertensive participants reported consuming 
fewer calories, but more nutrients overall. 
In a multivariate-adjusted model the association of total choline intake with the 
prevalence odds of hypertension differed by sex (Pinteraction = 0.04, Figure 3.1). 
Specifically, women consuming higher amounts of choline tended (P < 0.1) to have 
lower odds of prevalent hypertension compared to women consuming less choline 
(OR per 100 mg of choline [95% CI], 0.89 [0.77 – 1.02]).  In contrast, total choline 
intake had little to no association with the odds of hypertension in men (P = 0.54; 
graphed in Figure 3.2). There was no evidence for effect modification of the total 
choline intake—hypertension association by race/ethnicity, BMI or, among female 
participants, by post-menopausal status or use of hormone replacement therapy 
(Figure 3.1). 
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Figure 3.1 Associations between total choline intake and odds of hypertension in 2007-10 
National Health and Nutrition Examination Survey by subgroups. All models 
were adjusted for age, sex, race, education, poverty ratio, BMI and total calories 
unless the covariate was tested as an effect modifier, in which case it was entered 
in an interaction term; odds ratios for sex, race and BMI were based on n= 8,349 
due to missing data in the covariates; odds ratios for menopausal status and 
hormone replacement therapy use were based on n = 4,023 and n = 4,011 
respectively; odds ratios are expressed per 100 mg of total choline 
Because molecular forms of choline in diet could differ from supplemental forms, 
the separate associations of dietary and supplemental choline with hypertension were 
investigated. The dietary intake of choline—hypertension association was similar to 
the findings for total choline intake. Dietary choline was differentially associated with 
the odds of hypertension by sex (Pinteraction = 0.03), such that a protective association 
was observed only in women (0.89, [0.77 – 1.02]; Supplementary Figure 3.2 and 
Supplementary Figure 3.3).  
Subgroup
Overall
Sex
   Male
   Female
Race
   Non−Hispanic White
   Non−Hispanic Black
   Hispanic, Mexican−Amer ican, and others
BMI (kg m
2
)
   <18.5
   18.5−24.9
   25−29.9
   ³ 30
Post−menopause (women only)
   Yes
   No
Hormone replacement ther apy use (women only)
   Yes
   No
Odds ratio (95% CI)
0.98 (0.90−1.07)
1.03 (0.94−1.12)
0.89 (0.77−1.02)
0.98 (0.89−1.07)
1.02 (0.92−1.14)
0.98 (0.86−1.11)
1.17 (0.85−1.62)
0.95 (0.83−1.09)
0.97 (0.87−1.08)
1.01 (0.90−1.13)
0.86 (0.73−1.02)
0.89 (0.69−1.15)
0.92 (0.72−1.18)
0.84 (0.71−1.00)
P−value
0.68
0.04
0.70
0.53
0.81
0.49
0.5 1 1.5
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Figure 3.2  Example of predicted probabilities of having hypertension over a range of total 
choline intake for a male or female who were White, had a college degree, and 
had mean age (48 y), poverty ratio (3), BMI (28.7 kg/m2) and total caloric intake 
(2086.6 kcal/d) 
In 2007-10 NHANES the use of supplemental choline was rare, and doses were 
limited (Supplementary Table 3.2), hindering investigation of the dose-response 
relationships of supplemental choline with hypertension. Thus, supplemental choline 
intake was modeled as a binary variable (user vs. non-user).  In contrast to the sex-
dependent association of dietary choline and the odds of hypertension, supplemental 
choline use during the past 24 h was associated with lower odds of hypertension in 
both sexes (0.68 [0.49 – 0.92], Table 3.1). However, in the sensitivity analysis defining 
supplemental choline use during the past 30 d, the association was attenuated (0.83 
[0.61 – 1.13]). In a further analysis, which limited supplement users and non-users to  
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Table 3.1 Association between total, dietary and supplemental choline intake and prevalent 
odds of hypertension in 2007-10 National Health and Nutrition Examination Survey (n = 
9,227) 
    Age-adjusted analysis   Multivariate analysis* 
Choline 
Unit of 
comparison 
Odds 
ratio 95% CI P 
 
Odds 
ratio† 95% CI P 
Total intake 1 mg/day 1.00 (1.0, 1.001) 
0.50 
 
1.00 (0.999, 1.001) 
0.68 
 
100 mg/day‡ 1.01 (0.97, 1.06) 
 
0.98 (0.90, 1.07) 
Dietary 
intake 
1 mg/day 1.00 (1.0, 1.001) 
0.45  
1.00 (0.999, 1.001) 
0.72 
 
100 mg/day‡ 1.02 (0.97, 1.06)  0.98 (0.90, 1.07) 
Supplemental User vs. non-
user 
0.57 (0.44, 0.74) 
<0.0
001 
  0.68 (0.49, 0.92) 0.01 
* Adjusted for age, sex, race, education, poverty ratio, BMI and total calories 
† Estimates were based on n= 8,349 due to missing data in the covariates 
‡ Estimates were calculated from 1 mg/day models 
those participants with a consistent report of use in both the 24-h recalls and the 30-
day questionnaire, a statistically significant association between supplemental choline 
use and the odds of hypertension persisted (0.67 [0.48 – 0.94]).  
All results from the main analyses were confirmed in planned sensitivity analyses 
that first excluded participants with comorbidities, and second, limited the outcome 
definition to participants with 'definite' hypertension status. 
3.3.2 Associations between choline intake and blood pressure 
The majority of the participants included in the analysis of the blood pressure 
outcome (6,416 out of 6,554 total) were also included in the analysis of the 
hypertension outcome. The subset of participants who were included in the 
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hypertension outcome models, but who were excluded from the blood pressure 
outcome models (3,005 out of 9,227 total) were omitted because of the use of 
antihypertensive medications (n = 2,691) and zero or missing blood pressure (n = 
314). Thus, as expected, participants in the blood pressure outcome models had a 
lower average age and corresponding differences in age-related indices (e.g., lower 
proportion married, lower proportion post-menopausal, lower SBP and BMI, greater 
physical activity and caloric intake) compared to participants in the hypertension 
models.  
There was little to no association between total choline intake and blood pressure 
(change in SBP per 100 mg of choline ± SEM, -0.26 ± 0.22 mmHg, P = 0.23; change 
in DBP per 100 mg choline, -0.29 ± 0.19 mmHg, P = 0.12, Table 3.2). The findings for 
dietary choline and supplemental choline use were similarly null (Table 3.2), and there 
was no evidence for modification of the total choline intake—BP associations by sex, 
race/ethnicity, BMI or, among female participants, by post-menopausal status or use of 
hormone replacement therapy.  
Because the participants included in the blood pressure outcome models were 
younger than the participants included in the hypertension models, we investigated age 
as an effect modifier of choline—blood pressure association to understand if the lack 
of an association might be age-related. Modeling age as a dichotomy (≥ 65 vs. < 65 y), 
the choline—SBP association differed by age (Pinteraction < 0.0001) such that total 
choline intake was inversely associated with SBP among participants age ≥ 65 y but 
not among younger participants (-3.29 ± 0.67 mmHg, P < 0.0001 and 0.40 ± 0.22  
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Table 3.2 Linear associations between total, dietary and supplemental choline intake and blood 
pressure in 2007-10 National Health and Nutrition Examination Survey (n = 6,554) 
  
Systolic blood pressure   Diastolic blood pressure 
  
Age-adjusted 
analysis  
Multivariate 
analysis* 
 
Age-adjusted 
analysis  
Multivariate  
analysis* 
Choline 
Unit of 
comparis
on 
β SEM P 
 
β† SEM P 
 
β SEM P 
 
β† SEM P 
Total 
intake 
1 mg/day 0.007 0.002 
<0.0
01  
-0.003 0.002 0.23 
 
0.005 0.001 
0.00
02  
-0.003 0.002 0.12 
 
100 
mg/day‡ 
0.653 0.158 
  
-0.264 0.220 
 
 
0.514 0.135 
  
-0.291 0.185 
 
Dietary 
intake 
1 mg/day 0.007 0.002 0.01 
 
-0.002 0.002 0.26 
 
0.005 0.001 
0.00
01  
-0.003 0.002 0.13 
 
100 
mg/day‡ 
0.666 0.159 
  
-0.247 0.221 
 
 
0.519 0.135 
  
-0.284 0.185 
 
Supplem
ent 
User vs. 
non-user 
-2.207 1.080 0.04 
 
-0.635 1.060 0.55 
 
-0.31 1.058 0.77 
 
-0.645 1.135 0.95 
* Adjusted for age, sex, race, education, poverty ratio, BMI and total calories  
† Estimates were based on n= 5,939 due to missing data in the covariates 
‡ Estimates were calculated from 1 mg/day models 
mmHg, P = 0.07, respectively, Supplementary Table 3.3). Age did not modify the 
association of choline with DBP (Pinteraction = 0.86, Supplementary Table 3.3).  
3.4 Discussion 
This study investigated the association of choline intake with hypertension and 
blood pressure. Overall, the findings do not support an adverse effect of dietary 
choline on blood pressure, and do not fit the hypothesized direction of association. A 
higher total choline intake, comprised primarily of dietary sources of choline, tended 
to be associated with lower odds of hypertension limited to women only, and 
78 
supplemental choline use was statistically significantly associated with a lower odds of 
hypertension in both sexes. In analyses of choline and blood pressure, higher choline 
intake was associated with lower SBP, but only in adults aged ≥ 65 y.   
The hypothesis that higher dietary choline intake associates with an increased risk 
of hypertension is based on a plethora of studies (both human and animal) that 
reported direct and positive associations between the choline-derivative TMAO and 
cardiovascular outcomes. However, our findings, which show an inverse association 
of total or dietary choline intake with odds of hypertension and blood pressure, are 
consistent with other human studies that have reported associations between dietary 
choline intake and risk of atherosclerosis [19,20] and the development of CVD [21–
23]. A cross-sectional study in a Greek population showed that dietary choline intake 
was inversely associated with levels of inflammatory markers [19], while a cohort 
study observed no association between dietary choline and markers of inflammatory 
and atherosclerotic states [20]. Additionally, two other prospective cohort studies 
found no associations between dietary choline and incident CVD [21,22]. A cohort 
study in African Americans reported an inverse association of dietary choline with 
stroke incidence in the overall population, and with subclinical markers of CVD risk 
in women only [23]. To our knowledge, only one study reported that an increased 
dietary choline intake was associated with an increased CVD mortality, and the same 
study found no association with incident CVD [24]. Since a positive association was 
observed only with CVD mortality and not incidence, the dietary choline-CVD 
relationship may depend on the stage of the disease. For example, in patients with 
advanced CVD, dietary choline could exacerbate the risk of cardiovascular 
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complications, possibly through its role in hepatic lipid export [25,26] or via the 
production of TMAO. We attempted to test this hypothesis by excluding participants 
with existing CVD, but the effect estimates were unchanged. Furthermore, we did not 
observe differential choline-blood pressure associations across ranges of blood 
pressure (≥140/90 mmHg and <140/90 mmHg).  
It is noteworthy that among women, both total and dietary choline intake tended (P 
< 0.10) to be inversely associated with odds of hypertension, while supplemental 
choline use by both sexes showed a significant inverse association with odds of 
hypertension. The results of models for the hypertension outcome were not consistent 
with the results of models for the blood pressure outcome. A possible explanation for 
this inconsistency in findings is the difference in the age distribution between the 
participants in the hypertension model and the participants in the blood pressure 
model. Compared to the participants in the hypertension model, participants in the 
blood pressure model were younger and had different distributions on age-related 
traits as well. The differences in findings between the hypertension and blood pressure 
outcomes may arise due to these differences. If the choline—BP association differed 
by age, then different age distributions would contribute to the inconsistent findings 
for choline—hypertension and choline—BP. Indeed, the finding that choline was 
inversely associated with SBP only in participants age ≥ 65 y supports this explanation 
for the pattern of findings.  
Given the inverse associations, we speculated that a possible mechanism for the 
protective effect of dietary choline on blood pressure may involve increased 
endogenous production of a phosphatidylcholine (PC) molecule that is enriched in 
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docosahexaenoic acid (DHA). DHA has been shown to reduce blood pressure and 
heart rate [27] and improve vascular reactivity in generally healthy adults [28]. 
Endogenous synthesis of PC-DHA is catalyzed by phosphatidylethanolamine N-
methyltransferase (PEMT), an enzyme that is regulated by estrogen [29] A higher 
dietary choline intake has been shown to enhance the activity of the PEMT pathway 
and increase hepatic PC-DHA export among women [30].  In addition, animal data 
have demonstrated that female mice use more dietary choline to generate PC via the 
PEMT pathway than male mice [31]. These findings may collectively explain our 
observation of a borderline significant inverse association between dietary choline 
intake among women, but not men. Other mechanisms by which choline may benefit 
cardiovascular health include the reduction of plasma homocysteine [21] and 
vasodilation of vascular smooth muscle by the neurotransmitter acetylcholine [32]. 
Notably, reduced synthesis of acetylcholine is particularly prevalent among older 
adults [33,34], and this may contribute to the inverse association of total choline intake 
with SBP in this age group.  
Sources of choline might also affect its relationship with health outcomes. Based on 
24-h supplement usage information, we observed 32% lower odds of hypertension 
among supplemental choline users as compared to non-users. This effect estimate was 
diluted when 30-day supplement use information was used, indicating that 
measurement error likely existed in the categorization of choline supplement use. To 
address measurement error, we restricted the analysis to individuals who reported 
supplement use consistently on both the 24-hr recall and the 30-day questionnaire; 
there was a 33% reduction in the odds of hypertension associated with the use of a 
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choline supplement.  In addition to reducing measurement error, we tested for 
additional confounding by smoking status and by any dietary supplement use and 
found no change to the conclusion. 
The beneficial association of supplemental choline with the risk of hypertension 
may be mediated by the release of free choline molecules from choline bitartrate, the 
prevalent form of supplemental choline reported by users. Free choline is absorbed 
more rapidly than PC [35], the main form of choline in foods. A large proportion of 
absorbed free choline can be irreversibly oxidized to betaine in the intestinal cells and 
the liver [36]. Betaine is a methyl donor and osmolyte whose plasma concentration 
was inversely associated with several CVD risk factors, including blood pressure [37]. 
A potential increase in this metabolite following choline supplement use may mediate 
the observed beneficial association with hypertension. 
We acknowledge several limitations of the present study. First, the use of 24-hour 
recalls represents a snapshot in time of an individual’s diet. Intra-individual variation 
may dilute the effect estimates and could account for the reported non-significant 
findings. Second, misclassification of hypertension status could also bias the effect 
estimates toward the null. However, this issue may have limited influence because we 
found similar effect estimates when excluding participants with a less definitive 
diagnosis. Third, the limited number of supplement users and severe skewness in 
supplement dose data prevented an investigation of a dose-response relationship 
between supplemental choline and the outcomes. Related to this issue, we 
acknowledge that the inverse association observed by comparing users vs. non-users 
of choline supplements may have been confounded by lifestyle factor differences 
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between these groups leading to reverse causality. Adjustment for lifestyle-related 
confounders did not change the conclusion, although residual confounding may still 
remain. Last, reverse causality may be a more general issue given that hypertensive 
individuals may have modified their dietary patterns or taken dietary supplements in 
response to their diagnosis. Excluding individuals with CVD-related comorbidities did 
not substantially change the effect estimates, but it is not possible to overcome this 
limitation in this study design. 
Strengths of this study include use of both hypertension and blood pressure as 
outcomes to derive the conclusions, and testing for and demonstration of a sex-specific 
association. This study also highlights the possible importance of free choline found in 
supplements in relation to hypertension. Finally, by using samples drawn from a 
nationally representative dataset, results of this study are generalizable to the U.S. 
population. 
In conclusion, data from this cross-sectional study do not support a positive 
association between choline intake and blood pressure.  The tendency for an inverse 
association between total or dietary choline intake and odds of hypertension in women 
suggests that choline intake may have a beneficial association limited to this subgroup. 
Use of supplemental choline was associated with a lower odds of hypertension, 
suggesting that sources of choline may be important in determining the associations 
with disease risk.  
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CONCLUSION 
SUMMARY 
In this dissertation, the roles of diet in the metabolism of trimethylamine-N-oxide 
(TMAO), an emerging factor in cardiovascular disease (CVD), are examined. In 
Chapter 1, we show that consumption of fish, which is high in TMAO, yields 
substantially greater increases in circulating TMAO than eggs or beef, which contain 
high amounts of dietary TMAO precursors. TMAO response to food sources varies as 
a function of gut microbiome. Specifically, men with higher Firmicutes to 
Bacteroidetes microbial ratios exhibit greater TMAO responses to dietary precursor 
intakes.  
In Chapter 2, we show that absorption of orally consumed TMAO is near complete, 
and may occur largely by a process that is independent of gut microbes and hepatic 
flavin-containing monooxygenases (FMOs). In healthy men, TMAO exhibits fast 
turnover in the circulation with the majority being eliminated in urine. A small portion 
of the dose, however, is taken up by extrahepatic tissue in a manner that correlates 
with FMO3 G472A polymorphism.   
In Chapter 3, we further investigate the cross-sectional relationship between dietary 
choline and blood pressure in the 2007-10 National Health and Nutritional 
Examination Survey (NHANES). Despite being a precursor of TMAO, our data do not 
support a positive association between choline intake and blood pressure. Specifically, 
total or dietary choline intake tends to be inversely associated with odds of 
89 
hypertension in women, and use of supplemental choline is associated with lower odds 
of hypertension. 
STUDY IMPLICATIONS 
Evidence in this dissertation indicates that circulating concentrations of TMAO in 
healthy adults are temporarily elevated upon consumption of choline and TMAO food 
sources (eggs, beef and fish). Previous research has positively associated dietary 
choline with CVD risk due to its TMAO-raising characteristics. However, we 
demonstrate here that a source of TMAO in the body also comes from heart-healthy 
food such as fish. Food sources of choline and TMAO also contain nutrients that are 
critical for health, and thus caution is warranted when proposing dietary 
recommendations that restrict the intakes of certain foods because of their TMAO-
raising characteristics. 
Additionally, we show that FMOs and gut microbiota may influence TMAO 
metabolism. FMO3 G472A polymorphism correlates with the uptake of TMAO 
relative to trimethylamine into skeletal muscle, while gut microbiome composition is 
associated with individual TMAO production from choline-rich foods. The higher 
Firmicutes to Bacteroidetes ratio among men with greater TMAO production has also 
been associated with increased risk of obesity and metabolic syndrome; supporting the 
notion that gut microbiota and FMOs influence plasma TMAO and potentially CVD 
risk. 
90 
The dietary choline/TMAO—CVD relationship may depend on the health status of 
individuals. To this end, we traced the metabolic fates of orally consumed TMAO and 
show that it is rapidly and efficiently eliminated in healthy men. These results suggest 
that dietary TMAO may not chronically elevate circulating TMAO in healthy 
individuals, unlike the elevated baseline TMAO status that is common among cardiac 
or renal patients.  To further examine whether dietary sources of TMAO could be 
linked to disease in a non-patient population, we investigated the relationship of 
dietary choline with hypertension, a major public health concern and risk factor of 
CVD. Findings from the 2007-10 NHANES data do not support a positive association 
between choline intake and blood pressure or prevalence odds of hypertension. 
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SUPPLEMENTARY TABLES AND FIGURES 
Chapter 1. Trimethylamine-N-oxide (TMAO) response to animal source foods 
varies among healthy young men and is influenced by their gut microbiota 
composition: a randomized controlled trial 
Supplementary Table 1.1 Participant characteristics and baseline measures for high- and low-
TMAO producers 
 
High-TMAO 
Producers (n = 11) 
Low-TMAO 
Producers (n = 15)1 
Participant Characteristics   
Age (y) 29.2 ± 1.8 27.1 ± 1.6 
BMI (kg/m2) 24.8 ± 0.7 23.7 ± 0.6 
Genotype 
 
 
GG % 36 40 
GA % 55 47 
AA % 9 13 
  
 
Blood Chemistry Concentrations (all serum) 
HDL (mg/dL) 56 ± 5 56 ± 3 
LDL (mg/dL) 117 ± 10 124 ± 6 
Cholesterol (mg/dL) 176 ± 8 174 ± 8 
Triglycerides (mg/dL) 74 ± 11 74 ± 9 
Total bilirubin (mg/dL) 0.8 ± 0.1 0.8 ± 0.1 
Direct bilirubin (mg/dL) 0.2 ± 0.0 0.2 ± 0.0 
ALP (U/L) 70 ± 5 71 ± 3 
Cr (mg/dL) 1.1 ± 0.0 1.1 ± 0.0 
CK (U/L) 133 ± 16 147 ± 16 
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LDH (U/L) 161 ± 6 153 ± 4 
Amylase (U/L) 56 ± 4 52 ± 5 
Lipase (U/L) 135 ± 10 151 ± 14 
AST (U/L) 22 ± 1 21 ± 1 
ALT (U/L) 36 ± 2 32 ± 4 
GGT (U/L) 35 ± 2 30 ± 2 
Total protein (g/dL) 7.7 ± 0.1 7.6 ± 0.1 
Albumin (g/dL) 4.2 ± 0.0 4.4 ± 0.0 
BUN (mg/dL) 14 ± 1 14 ± 1 
  
 
Cell Counts 
 
 
WBC (×103/µL) 5.6 ± 0.4 5.5 ± 0.2 
Lymphocytes (×103/µL) 1.9 ± 0.2 1.9 ± 0.1 
Monocytes (×103/µL) 0.2 ± 0.0 0.2 ± 0.0 
Granulocytes (×103/µL) 3.5 ± 0.4 3.4 ± 0.2 
RBC (×103/µL) 5.2 ± 0.1 5.2 ± 0.1 
  
 
TMAO (nmol/mL) 3.4 ± 0.5 3.4 ± 0.2 
TMA (pmol/mL) 19.0 ± 1.9 20.4 ± 1.4 
DMA (nmol/mL) 1.9 ± 0.1 2.0 ± 0.0 
MA (nmol/mL) ND ND 
  
 
Urinary Methylamine Excretion 
TMAO (nmol/mmol Cr) 27.4 ± 2.1 28.7 ± 1.7 
TMA (nmol/mmol Cr) 0.2 ± 0.0 0.1 ± 0.0 
DMA (nmol/mmol Cr) 25.8 ± 0.5 27.7 ± 0.5 
MA (nmol/mmol Cr) 5.1 ± 1.1 3.9 ± 0.4 
1 No differences were detected between high- and low-TMAO producers in the participant 
characteristics and baseline measures.  
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Chapter 2. The metabolic fate of isotopically labeled trimethylamine-N-oxide 
(TMAO) in humans 
 
Supplementary Figure 2.1 A) Plasma unlabeled trimethylamine-N-oxide (d0-TMAO) 
concentration remained unchanged throughout the 6-h study period. B) Urinary unlabeled 
TMAO concentration did not change statistically from baseline to 24-h post study. Data was 
analyzed using repeated measure mixed linear model with P = 0.05 threshold and the Tukey-
Kramer post-hoc test for multiple comparison correction. Values are mean ± SD for A) and 
SEM for B); n = 40 per time point. 
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Supplementary Figure 2.2 FMO3 472GA genotype exhibited a lower d9-TMAO:d9-TMA 
enrichment ratio than the wild-type GG genotype. Data was analyzed using t-test with P = 
0.05 threshold and the Bonferroni adjustment for multiple comparison. Values are mean ± 
SEM; n = 3 per genotype per metabolite. Abbreviation:  d9-TMA = Deuterium-labeled methyl 
d9-trimethylamine; d9-TMAO = d9-trimethylamine-N-oxide 
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Chapter 3. Relationship of choline intake with blood pressure in the National 
Health And Nutrition Examination Survey 2007-10 
Supplementary Methods 
The primary analyses and statistically significant results were followed by three 
planned sensitivity analyses. First, participants with <3 blood pressure readings were 
excluded. Second, participants with CVD endpoints defined as self-reporting of 
congestive heart failure, coronary heart disease, angina, heart attack or stroke were 
excluded. Finally, hypertension status was categorized into “definite”, “probable” or 
“possible” based on each participant’s available data. Definite was defined as the 
presence of 2 or all 3 classification features, including doctor’s diagnosis and 
medication use, or doctor’s diagnosis and high blood pressure, or doctor’s diagnosis, 
medication use and high blood pressure. Probable status was defined as presence of 1 
or 2 classification features, including doctor’s diagnosis only, or medication use and 
high blood pressure. Possible status was defined as the remaining categories, including 
medication use only or high blood pressure only. 
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Supplementary Tables 
Supplementary Table 3.1 Participant characteristics in 2007-10 National Health and Nutrition 
Examination Survey 
  
Hypertensive 
(n=3933)* 
Non-
hypertensive 
(n=5294)† 
Total for 
hypertension 
analysis 
(n=9227)‡ 
 
Total for 
blood pressure 
analysis 
(n=6554)§ 
Means SD Means SD Means SD 
 
Means SD 
Exposure 
         Energy-adjusted choline 
intake (mg/day)||¶ 326 107 314 112 319 110 
 
316 112 
Outcomes         
Systolic blood pressure 
(mmHg)|| 134 20 115 11 121 17 
 
118 15 
Diastolic blood pressure 
(mmHg)|| 73 14 69 10 70 12 
 
71 11 
          Demographics 
         Male (%) 47.5 
 
48.0 
 
47.8 
  
49.4 
 Age (y)|| 58.7 14.5 42.0 14.7 48.0 16.7 
 
43.5 15.3 
Race/ethnicity (%)|| 
             Non-Hispanic White|| 73.7 
 
69.7 
 
71.2 
  
70.0 
     Non-Hispanic Black|| 13.9 
 
9.3 
 
11.0 
  
9.8 
     Mexican American, 
Hispanic, Others|| 12.4 
 
21.0 
 
17.9 
  
20.2 
 Ratio of family income to 
poverty 3.0 1.6 3.1 1.6 3.0 1.6 
 
3.1 1.7 
Education level (%)|| 
             < 9th grade|| 7.6 
 
5.1 
 
6.0 
  
5.4 
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    9-11th grade|| 14.2 
 
11.5 
 
12.5 
  
11.8 
     High school|| 26.6 
 
22.7 
 
24.1 
  
23.0 
     College 29.6 
 
29.8 
 
29.7 
  
30.3 
     Graduate|| 22.0 
 
31.0 
 
27.7 
  
29.6 
 Body mass index (kg/m2)|| 30.9 7.1 27.5 6.0 28.7 6.6 
 
27.8 6.2 
Married (%)|| 61.2 
 
55.8 
 
57.8 
  
55.8 
 Moderate-vigorous 
activities (h/wk)|| 8.8 15.3 12.8 18.1 11.3 17.2 
 
12.5 17.9 
Smoking status (%)|| 
             Non-smoker|| 50.5 
 
56.3 
 
54.2 
  
55.4 
     Former smoker|| 32.8 
 
21.5 
 
25.6 
  
22.1 
     Current smoker|| 16.6 
 
22.2 
 
20.1 
  
22.4 
 Post-menopausal (%)|| 78.3 
 
31.2 
 
48.6 
  
35.7 
 Hormone replacement 
therapy usage (%)|| 35.9 
 
15.8 
 
23.2 
  
17.8 
           Intakes per day¶ 
         Total energy (kcal)|| 1982 795 2143 844 2087 831 
 
2146 853 
Energy-adjusted fat (g)|| 77 17 74 18 75 18 
 
74 18 
Energy-adjusted 
cholesterol (g)|| 281 144 267 154 278 151 
 
269 154 
Energy-adjusted protein 
(g) 80 19 79 21 79 20 
 
79 21 
Energy-adjusted sodium 
(mg) 3355 871 3344 883 3348 879   3332 887 
Energy-adjusted folate 
(dietary folate 
equivalents)|| 832 551 736 486 770 512 
 
750 516 
Energy-adjusted vitamin 
B6 (mg) 6.1 15.7 5.2 12.3 5.5 13.6 
 
5.4 12.8 
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* Due to missing values, final sample sizes varied: systolic blood pressure (n = 3,841), 
diastolic blood pressure (n = 3,813), ratio of family income to poverty (n = 3,612), education 
(n = 3,926), body mass index (n = 3,868), % married (n = 3,931), moderate-vigorous activities 
(n = 3,921), % post-menopausal (women only; n = 1,920), hormone replacement therapy 
usage (women only; n = 1,911) 
† Due to missing values, final sample sizes varied: ratio of family income to poverty (n = 
4,834), education (n = 5,289), body mass index (n = 5,263), % married (n = 5,291), moderate-
vigorous activities (n = 5,283), smoking status (n = 5,293), % post-menopausal (women only; 
n = 2,514), hormone replacement therapy usage (women only; n = 2,510) 
‡ Due to missing values, final sample sizes varied: systolic blood pressure (n = 9,135), 
diastolic blood pressure (n = 9,107), ratio of family income to poverty (n = 8,446), education 
(n = 9,215), body mass index (n = 9,131), % married (n = 9,222), moderate-vigorous activities 
(n = 9,204), smoking status (n = 9,226), % post-menopausal (women only; n = 4,434), 
hormone replacement therapy usage (women only; n = 4,421) 
§ Due to missing values, final sample sizes varied: ratio of family income to poverty (n = 
5,985), education (n = 6,545), body mass index (n = 6,511), % married (n = 6,551), moderate-
vigorous activities (n = 6,541), smoking status (n = 6,553), % post-menopausal (women only; 
n = 3,058), hormone replacement therapy usage (women only; n = 3,051) 
|| Hypertensive group differed significantly (p < 0.05) from the non-hypertensive based on a 
Rao-Scott likelihood ratio chi-square test (categorical variables) or a T-test (continuous 
variables); all tests were adjusted for complex survey design 
¶ Total intake (diet and supplement) was used and standardized to 2,000 kcal/d for all nutrients 
  
Energy-adjusted vitamin 
B12 (μg)|| 55.4 331.3 37.1 220.8 43.5 265.2 
 
40.4 245.6 
  99  
 
Supplementary Table 3.2 Choline intake from diet and supplements in 2007-10 National 
Health and Nutrition Examination Survey 
* Hypertensive group differed significantly (p < 0.05) from the non-hypertensive based on a 
Rao-Scott likelihood ratio chi-square test (categorical variables) or a T-test (continuous 
variables); all tests were adjusted for complex survey design 
  
 
Hypertensive 
(n=3933)* 
Non-
hypertensive 
(n=5294)† 
Total for 
hypertension 
analysis 
(n=9227)‡ 
 
Total for 
blood pressure 
analysis 
(n=6554)§ 
Means 
(n) SD 
Means 
(n) SD 
Means 
(n) SD 
 
Means 
(n) SD 
Energy-adjusted dietary 
choline intake (mg/day)* 
326 
(3,933) 
106 313 
(5,294) 
111 318 
(9,227) 
110 
 
315 
(6,554) 
112 
Supplemental choline use 
over 24 h (%)* 
2.5 
(3,933) 
 4.2 
(5,294) 
 3.6 
(9,227) 
 
 
4.0 
(6,554) 
 
Supplemental choline 
intake over 24 h (mg/day) 
38 
(100) 
71 24 
(176) 
33 27 
(276) 
46 
 
24 
(219) 
34 
Supplemental choline use 
over 30 days (%)* 
3.1 
(3,932) 
 4.7 
(5,292) 
 4.2 
(9,224) 
 
 
4.5 
(6,552) 
 
Supplemental choline 
intake over 30 days 
(mg/day) 
51 
(106) 
88 
24 
(213) 
45 
31 
(319) 
61 
 
27 
(263) 
49 
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Supplementary Table 3.3 Age-dependent associations between total choline intake and blood 
pressure in 2007-10 National Health and Nutrition Examination Survey* 
  
Systolic blood pressure 
 
Diastolic blood pressure 
 
Unit of 
comparison β† SEM 
P-
interaction 
 
β† SEM 
P-
interaction 
Age ≥ 65 y 1 mg/day -0.033 0.007 
< 0.0001 
 
-0.001 0.002 
0.86 
 
100 mg/day‡ -3.293 0.671 
 
-0.147 0.194 
Age < 65 y 1 mg/day 0.004 0.002 
 
-0.006 0.005 
 
100 mg/day‡ 0.405 0.222 
 
-0.063 0.462 
* Adjusted for sex, race, education, poverty ratio, BMI and total calories  
† Estimates were based on n= 5,939 due to missing data in the covariates 
‡ Estimates were calculated from 1 mg/day models 
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Supplementary Figures 
 
Supplementary Figure 3.1 Participant flow charts for A) the analysis of hypertension and B) 
blood pressure 
 
Supplementary Figure 3.2 Sex-dependent associations between dietary choline intake and 
odds of hypertension in 2007-10 National Health and Nutrition Examination Survey. Models 
were adjusted for age, sex, race, education, poverty ratio, BMI and total calories; odds ratios 
were based on n= 8,349 due to missing data in the covariates and are expressed per 100 mg of 
dietary choline 
Subgroup
Overall
Sex
   Male
   Female
Odds ratio (95% CI)
0.98 (0.90−1.07)
1.03 (0.95−1.12)
0.89 (0.77−1.02)
P−value
0.72
0.03
0.65 1 1.2
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Supplementary Figure 3.3 Example of predicted probabilities of having hypertension over a 
range of dietary choline intake for a male or female who were White, had a college degree, 
and had mean age (48 y), poverty ratio (3), BMI (28.7 kg/m2) and total caloric intake (2086.6 
kcal/d) 
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